Recombinant adeno-associated viral vectors in plants

By expressing AAV proteins in plants using separate plasmids with optimized regulatory elements, the method achieves consistent high yield and improved purity and safety in AAV production, addressing inefficiencies in conventional cell culture methods.

WO2026236458A1PCT designated stage Publication Date: 2026-11-12VECPROBIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027056
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

Smart Images

  • Figure US2026027056_12112026_PF_FP_ABST
    Figure US2026027056_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to nucleic acid sequences encoding plant-based Adeno-associated viruses (AAV) production components comprising a split-Cap and split-Rep plasmid system. Also disclosed are methods of producing functional AAV particles using these nucleic acid sequences in plants. Production of AAV in plants as disclosed herein provides many benefits over conventional processes, such as efficiency, cost, yield, scalability, and safety. These methods preserve the natural stoichiometry of AAV vectors, prevent toxicity from overexpression, and reduce recombination issues, thereby providing consistent AAV vector production.
Need to check novelty before this filing date? Find Prior Art

Description

VCPRO.006WO PCT APPLICATION RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS IN PLANTSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 802,900, filed May 9, 2025, which is hereby expressly incorporated by reference in its entirety.REFERENCE TO SEQUENCE LISTING

[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided in a file entitled SeqlistVCPRO006WO.xml, which was created on May 6, 2026, and is 112,269 bytes in size. The information in the electronic Sequence Listing is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION

[0003] The present disclosure relates to nucleic acid sequences encoding components of adeno-associated virus (AAV), such as those that have been codon-optimized for expression in plants, and the proteins that are expressed from these nucleic acid sequences. Also disclosed are methods of producing functional AAV particles using these nucleic acid sequences in plants. Production of AAV in plants as disclosed herein offers many benefits as compared to conventional processes of virus production, including efficiency, cost, purity, yield, scalability, and safety.BACKGROUND OF THE INVENTION

[0004] Adeno-associated viruses (AAV) have found great popularity for use in both in vitro transduction into human cells and in vivo transduction for gene therapy due to its minimal immunogenicity, high efficacy, and relative safety. AAV particles are typically produced in mammalian or insect cell culture systems, but maintaining these cell cultures, purification of the AAV particles, and obtaining sufficient viral titers is difficult and expensive. There is a present need for improved methods for producing AAV particles.SUMMARY OF THE INVENTION

[0005] Described herein are embodiments directed to Adeno-associated viruses (AAV) particles generated in plants, preferably wherein the VP1, VP2, VP3, Rep 78, and Rep52 are expressed from different plasmids, which beneficially allows optimization of the stoichiometry of these molecules by utilizing preferred regulatory elements that control expression of the genes in a preferred manner, such as by utilizing one or more nucleic acids encoding a promoter described in any one or more of SEQ ID NOs: 28-45, a UTR comprising the nucleic acid sequence of any one of SEQ ID NOs: 46-52, a terminator comprising the nucleic acid sequence of any one of SEQ ID NOs: 53-61, and or a helper gene of any one of SEQ ID NOs: 13-27.

[0006] Preferred aspects described herein relate to the following numbered alternatives:1. A system for AAV production comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids: andwherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids.2. The system of aspect 1, wherein nucleic acids encoding the VP1. VP2, and / or VP3 proteins are from more than one AAV serotype.3. The system of any of the preceding aspects, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.4. The system of any of the preceding aspects, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).5. The system of any of the preceding aspects, further comprising a plasmid comprising a nucleic acid encoding a helper gene.6. The system of any of the preceding aspects, wherein the VP1, VP2, and VP3 nucleic acid sequences are any one or more of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.7. The system of any of the preceding aspects, wherein the Rep78 and Rep52 nucleic acid sequences are any one or more of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.8. A method for AAV production comprising:i. preparing AAV plasmids comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids;wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids:ii. introducing said plasmids into a vector capable of infecting a plant cell;iii. delivering said vector into a plant, preferably through a transient expression method; andiv. processing infiltrated leaves for AAV particles.9. The method of aspect 8, wherein the AAV produced is suitable for therapeutic use in a subject.10. The method of aspect 9, wherein the subject is a human.11. The method of any of the preceding method aspects, wherein the vector is Agrobacterium tumefaciens.12. The method of any of the preceding method aspects, wherein the plant is Nicotiana benthamiana.13. The method of any of the preceding method aspects, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.14. The method of any of the preceding method aspects, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.15. The method of any of the preceding method aspects, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).16. The method of any of the preceding method aspects, further comprising a plasmid comprising a nucleic acid encoding a helper gene.17. The method of any of the preceding method aspects, wherein the VP1, VP2, and VP3 nucleic acid sequences are any one or more of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.18. The method of any of the preceding method aspects, wherein the Rep78 and Rep52 nucleic acid sequences are any one or more of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.19. A system for AAV production comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; and c) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene.20. The system of aspect 19. wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.21. The system of any of aspects 19 or 20, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.22. The system of any of aspects 19-21, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).23. The system of any of aspects 19-22, further comprising a plasmid comprising a nucleic acid encoding a helper gene.24. The system of any of aspects 19-23, wherein the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.25. The system of any of aspects 19-24, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.26. The system of any of aspects 19-25, wherein the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins.27. The system of aspect 26, wherein the transgene comprises TNFa, IL-2 or IL-4.28. A method for increasing genomic titer, capsid titer, and / or empty / full ratio of an AAV comprising a transgene, comprising introducing the system of any one of aspects 19-27 into a vector capable of infecting a plant cell, delivering said vector into a plant, preferably through a transient expression method, and processing infiltrated leaves for AAV particles.29. A method for reducing neutralizing antibody response in a subject to an AAV comprising a transgene, comprising introducing the system of any one of aspects 19-27 into a vector capable of infecting a plant cell, delivering said vector into a plant preferably through a transient expression method, and processing infiltrated leaves for AAV particles, wherein the AAV particles produced are administered to a subject.30. A method for AAV production comprising:i. preparing AAV plasmids comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins;c) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; ii. introducing said plasmids into a vector capable of infecting a plant cell;iii. delivering said vector into a plant through a transient expression method; andiv. processing infiltrated leaves for AAV particles.31. The method of aspect 30, wherein the AAV produced is suitable for therapeutic use in a subject.32. The method of aspect 31, wherein the subject is a human.33. The method of any one of aspects 29-32, wherein the vector is Agrobacterium tumefaciens.34. The method of any one of aspects 29-33, wherein the plant is Nicotiana benthamiana.35. The method of any one of aspects 29-34, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.36. The method of any one of aspects 29-35, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.37. The method of any one of aspects 29-36, wherein the VP1 , VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).38. The method of any one of aspects 29-37. further comprising a plasmid comprising a nucleic acid encoding a helper gene.39. The method of any one of aspects 29-38, wherein the VPL VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.40. The method of any one of aspects 29-38, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.41. The composition of any of aspects 29-40, wherein the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins.42. The composition of aspect 41, wherein the transgene comprises TNFa, IL-2, or IL-4.43. The system or method of any one of aspects, 5. 16. 23. or 38, wherein the helper gene comprises the nucleic acid sequence of any one of SEQ ID NOs: 13-27 or a sequence disclosed in Table 1.44. The system or method of any one of the preceding aspects, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a promoter comprising the nucleic acid sequence of any one of SEQ ID NOs: 28-45 or a sequence disclosed in Table 1.45. The system or method of any one of the preceding aspects, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a UTR comprising the nucleic acid sequence of any one of SEQ ID NOs: 46-52 or a sequence disclosed in Table 1.46. The system or method of any one of the preceding aspects, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a terminator comprising the nucleic acid sequence of any one of SEQ ID NOs: 53-61 or a sequence disclosed in Table 1.BRTEF DESCRIPTION OF THE DRAWINGS

[0007] In addition to the features described above, additional features and variations will be readily apparent from the following descriptions of the drawings and exemplary embodiments. It is to be understood that these drawings depict typical embodiments and are not intended to be limiting in scope.

[0008] FIG. 1A depicts a summary of factors influencing the demand for AAV production in plants.

[0009] FIG. IB depicts a summary of advantages associated with AAV production in plants.

[0010] FIG. 1C depicts an overview of how AAV can be produced in plants.

[0011] FIG. 2A depicts AAV yield variability observed using the traditional three vector (Rep, Cap, Helper) system and a schematic of a proposed system separating VP1, VP2, and VP3 and Rep 52 and 78 onto different plasmids.

[0012] FIG. 2B depicts results for the “split system” for Cap and Rep proteins evaluating protein level expression of individual Capsid and Rep via western blot. Further, the start sites for each Capsid protein isoform were manipulated to determine which start sites could provide correct stoichiometry of VP1 / 2 / 3.

[0013] FIG. 3A depicts the results of an evaluation of the different promoter, 5’UTR, and terminator combinations in the split-system plasmids using GFP expression.

[0014] FIG. 3B depicts the results of an assessment of batch-to-batch consistency observed in the capsid titer of plant-produced AAV9 by ELISA (upper panel). FIG. 3B further depicts the results of an assessment of empty to full particle ratio in crude plant-produced AAV9.

[0015] FIG. 3C depicts the results of an assessment of VP1, VP2, and VP3 in plant-produced AAV2-CMV-EGFP and HEK293-produced AAV2-CMV-EGFP.

[0016] FIG. 3D depicts the results of an assessment of GFP mRNA expression in various tissues of non-human primates following dosing with Plant AAV9-CMVGFP or HEK AAV9-CMV-GFP.

[0017] FIG. 3E summarizes findings from the preceding figures.

[0018] FIG. 4A depicts a summary of a comparison of properties, including average yield, full particles in crude lysate, % full particles post purification, endotoxin levels,bacteriostasis and fungistasis, sterility test, and mycoplasma test, between Plant-AAV9-CMV-GFP and Mammalian-AAV9-CMV-GFP.

[0019] FIG. 4B depicts the results of an assessment comparing capsid titer, aggregation, and diameter between Plant-Produced AAV9-CMV-EGFP and HEK293-Produced AAV9-CMV-EGFP.

[0020] FIG. 4C depicts the results of an assessment comparing post-translational modification between Plant-Produced AAV9-CMV-EGFP and HEK293-Produced AAV9-CMV-EGFP.

[0021] FIG. 4D depicts a proposed study design for comparability testing of Plant-Produced AAV9-CMV-EGFP and HEK293-Produced AAV9-CMV-EGFP in non-human primates (NHP). FIG. 4E depicts fold change of Plant AAV9-CMV-GFP mRNA expression relative to HEK AAV9-CMV-GFP expression by qPCR in treated NHP tissues (IV and IT delivery) (left panel).

[0022] FIG. 4E depicts Western blot quantification of GFP protein expression in treated NHP tissues (IV and IT delivery) (right panel).

[0023] FIG. 4F depicts the results of an assessment of neutralizing antibody responses elicited in NHPs treated with Plant-Produced AAV9-CMV-EGFP or HEK293-Produced AAV9-CMV-EGFP.

[0024] FIG. 4G summarizes findings from FIGs. 4A-4F.

[0025] FIG. 5 depicts a list of helper genes that were tested in the “split system” for Cap and Rep proteins described herein and their function.

[0026] FIGs. 6A and 6B depict results of the evaluation of 14 different combinations of helper genes tested in the “split system” for Cap and Rep proteins described herein.

[0027] FIG. 7 depicts the results of an assessment of AAV yield via genomic titer for the different helper gene combinations of FIGs. 6 A and 6B.

[0028] FIG. 8A depicts an assessment of VP1, VP2, and VP3 levels for the different helper gene combinations of FIGs. 6A and 6B.

[0029] FIG. 8B depicts an assessment of Rep78 and Rep52 for the different helper gene combinations of FIGs. 6A and 6B.

[0030] FIG. 9A and 9B depict total AAV yield when microRNA-regulated constructs are used to suppress transgene expression during manufacturing of AAV6.2-eGFP (FIG. 9A) and AAV6.2-BAX (FIG. 9B).

[0031] FIG. 10 depicts a table for a prophetic experiment where production of AAV vectors encoding toxic inflammatory cytokines TNFa, IL2, and IL4 is tested in plants.

[0032] FIG. HA depicts rAAV9 vectors expressing cytotoxic cytokines TNFa. IL-4, and IL-2 were produced in N. benthamiana host plants to high genomic titer (>lel4vg / kg) comparable or higher than control EGFP AAV9 vectors (N=4).

[0033] FIG. 11B depicts rAAV9 vectors expressing cytotoxic cytokines TNFa, IL-4, and IL-2 are produced in N. benthamiana host plants to high capsid titer (>3el5cp / kg) comparable or higher than control EGFP AAV9 vectors (N=4).

[0034] FIG. 11C depicts rAAV9 vectors expressing cytotoxic cytokines TNFa, IL-4, and IL-2 are produced in N. benthamiana host plants with Empty to Full capsid to genome ratios (E / F) in crude plant lysate higher than control EGFP AAV9 vectors (N=4).DETAILED DESCRIPTION

[0035] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.

[0036] Using conventional Rep and Cap gene sequences for producing Adeno-associated viruses (AAV) in plants can lead to variability in AAV yield. To understand the cause of this variability, the expression levels and stoichiometry of the Cap proteins (VP1, VP2, VP3), and the Rep proteins (Rep 78 and Rep 52) were analyzed. It was found that in plants, the regulation and expression of these proteins have batch-to-batch variability that likely generates the variability in the AAV yield. Therefore, a split system was designed, wherein the cap proteins (VP 1 / 2 / 3) andRep proteins (Rep78 / 52) were expressed separately. This system was further modified by using different promoters, Kozak sequences, and start sites to achieve the right stoichiometry. These modifications provided consistently high AAV yield.

[0037] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. For purposes of the present disclosure, the following terms are defined below.

[0038] The articles “a” and “an” are used herein to refer to one or to more than one (for example, at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0039] By “about” is meant a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0040] Throughout this specification, unless the context requires otherwise, the words “comprise,” “comprises,” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of’ is meant including any elements listed after the phrase and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they materially affect the activity or action of the listed elements.

[0041] The practice of the present disclosure will employ, unless indicated specifically to the contrary, conventional methods of molecular biology and recombinant DNA techniques within the skill of the art.

[0042] The terms “function” and “functional” as used herein refer to a biological or enzymatic function.

[0043] The term “isolated” as used herein refers to material that is substantially or essentially free from components that normally accompany it in its native state. For example, an“isolated protein” includes a protein that has been purified from the milieu or organism in its naturally occurring state.

[0044] The terms “nucleic acid” or “nucleic acid molecule” as used herein refer to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and / or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, or phosphoramidate. The term “nucleic acid molecule” also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single-stranded or double-stranded. “Oligonucleotide” can be used interchangeably with nucleic acid and can refer to either double- stranded or singlestranded DNA or RNA. A nucleic acid or nucleic acids can be contained in a nucleic acid vector or nucleic acid construct (e.g., plasmid, virus, adeno-associated virus (AAV), bacteriophage, cosmid. fosmid, phagemid. bacterial artificial chromosome (BAC), yeast artificial chromosome (YAC), or human artificial chromosome (HAC)) that can be used for amplification and / or expression of the nucleic acid or nucleic acids in various biological systems. Typically, the vector or construct will also contain elements including but not limited to promoters, enhancers, terminators, inducers, ribosome binding sites, translation initiation sites, start codons, stop codons, polyadenylation signals, origins of replication, cloning sites, multiple cloning sites, restrictionenzyme sites, epitopes, reporter genes, selection markers, antibiotic selection markers, targeting sequences, peptide purification tags, or accessory genes, or any combination thereof.

[0045] A nucleic acid or nucleic acid molecule can comprise one or more sequences encoding different peptides, polypeptides, or proteins. These one or more sequences can be joined in the same nucleic acid or nucleic acid molecule adjacently, or with extra nucleic acids in between, e.g.. linkers, repeats, or restriction enzyme sites, or any other sequence that is 1, 2, 3, 4, 5, 6, 7. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 300, 400, 500, 1000, 2000, 3000, 4000, or 5000 bases long, or any length in a range defined by any two of the aforementioned lengths. The term “downstream” on a nucleic acid as used herein refers to a sequence being after the 3 ’-end of a previous sequence, on the strand containing the encoding sequence (sense strand) if the nucleic acid is double- stranded. The term “upstream” on a nucleic acid as used herein refers to a sequence being before the 5 ’-end of a subsequent sequence, on the strand containing the encoding sequence (sense strand) if the nucleic acid is double-stranded. The term “grouped” on a nucleic acid as used herein refers to two or more sequences that occur in proximity either directly or with extra nucleic acids in between, e.g., linkers, repeats, or restriction enzyme sites, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 300, 400, 500, 1000, 2000, 3000, 4000, or 5000 bases long, or any length in a range defined by any two of the aforementioned lengths, but generally not with a sequence in between that encodes for a functioning or catalytic polypeptide, protein, or protein domain.

[0046] The term “codon optimized” regarding a nucleic acid as used herein refers to the substitution of codons of the nucleic acid to enhance or maximize translation in a host of a particular species without changing the polypeptide sequence based on species-specific codon usage biases and relative availability of each aminoacyl-tRNA in the target cell cytoplasm. Codon optimization and techniques to perform such optimization are known in the art. Additionally, synthetic codon- optimized sequences can be obtained commercially from DNA sequencing services. Those skilled in the art will appreciate that gene expression levels are dependent on many factors, such as promoter sequences and regulatory elements. As noted for most bacteria, small subsets of codons are recognized by tRNA species leading to translational selection, which can be an important limit on protein expression. In this aspect, many synthetic genes can be designed to increase their protein expression level. In some embodiments, codon optimization of a gene for acertain organism results in a level of expression of the gene at least 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, or 1000% of the level of expression with a non-codon optimized or wild-type gene sequence.

[0047] The nucleic acids described herein comprise nucleobases. Primary, canonical, natural, or unmodified bases are adenine, cytosine, guanine, thymine, and uracil. Other nucleobases include but are not limited to purines, pyrimidines, modified nucleobases, 5-methylcytosine, pseudouridine, dihydrouridine, inosine, 7-methylguanosine, hypoxanthine, xanthine, 5,6-dihydrouracil, 5-hydroxymethylcytosine, 5 -bromouracil, isoguanine, isocytosine, aminoallyl bases, dye-labeled bases, fluorescent bases, or biotin-labeled bases.

[0048] The terms “peptide”, “polypeptide”, and “protein” as used herein refer to macromolecules comprised of amino acids linked by peptide bonds. The numerous functions of peptides, polypeptides, and proteins are known in the art, and include but are not limited to enzymes, structure, transport, defense, hormones, or signaling. Peptides, polypeptides, and proteins are often, but not always, produced biologically by a ribosomal complex using a nucleic acid template, although chemical syntheses are also available. By manipulating the nucleic acid template, peptide, polypeptide, and protein mutations such as substitutions, deletions, truncations, additions, duplications, or fusions of more than one peptide, polypeptide, or protein can be performed. These fusions of more than one peptide, polypeptide, or protein can be joined in the same molecule adjacently, or with extra amino acids in between, e.g., linkers, repeats, epitopes, or tags, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, or 300 bases long, or any length in a range defined by any two of the aforementioned lengths.

[0049] In some embodiments, the nucleic acid or peptide sequences presented herein and used in the examples are optimized for plants but may also function in other organisms such as bacteria, fungi, protozoans, or animals. In other embodiments, nucleic acid or peptide sequences sharing 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%. or 100% similarity, or any percentage within a range defined by any two of the aforementioned percentages of similarity to the nucleic acid or peptide sequences presented herein and used in the examples can also be used with no effect or little effect on the function of the sequences in biological systems. As used herein, the term “similarity” refers to a nucleic acid or peptide sequence having the same overall order of nucleotide or amino acids, respectively, as atemplate nucleic acid or peptide sequence with specific changes such as substitutions, deletions, repetitions, or insertions within the sequence. In some embodiments, two nucleic acid sequences sharing as low as 0%, 10%, 20%. 30%, 40%, 50%, 60%, 70%. 80%, 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98%, or 99% similarity can encode for the same polypeptide by comprising different codons that encode for the same amino acid during translation.

[0050] As used herein, the terms "virion." "virus or viral vector" and "viral particle" are interchangeably used, unless otherwise indicated.

[0051] As used herein, the term "packaging" refers to the events including production of single-strand viral genomes, assembly of coat (capsid) proteins, encapsulation of viral genomes, and the like. When an appropriate plasmid vector (normally, a plurality of plasmids) is introduced into a cell line that allows packaging under an appropriate condition, recombinant viral particles (i.e., virions, viral vectors) are constructed and secreted into the culture.

[0052] Viruses of the Parvoviridae family are small DNA animal viruses characterized by their ability to infect particular hosts, among other factors. Specifically, the family Parvoviridae is divided between two subfamilies: the Parvovirinae, which infect vertebrates, and the Densovirinae, which infect insects. The subfamily Parvovirinae (members of which are herein referred to as parvoviruses) includes the genus Dependovirus, which, under most conditions, requires coinfection with a helper virus such as adenovirus, vaccinia virus, or herpes virus for productive infection in cell culture. Dependovirus includes adeno-associated virus (AAV), which normally infects humans (e.g., serotypes 2, 3A, 3B, 5, and 6) or primates (e.g., serotypes 1, 4, and rhlO), and related viruses that infect other warm-blooded animals (e.g., bovine, canine, equine, and ovine adeno-associated viruses and bocaviruses).

[0053] In some embodiments, a composition or system for AAV production is provided, comprising: a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; and wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids. In some embodiments, the nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype. In some embodiments, the nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio(VP1 :VP2:VP3). Tn some embodiments, the composition for AAV production further comprises a plasmid comprising a nucleic acid encoding a helper gene. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of Table 1. In some embodiments, the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of Table 1.Table 1: SequencesDescription SequenceCAP9 FL optimized Kozak GGGTTT(SEQ ID NO: 1)Rep2 FL optimized Kozak GCCACC(SEQ ID NO: 2)CAP9 FL optimized Coding ATGGCTGCTGATGGATATCTTCCAGATTGGCTTGAA (SEQ ID NO: 3) GATAATCTTTCTGAAGGAATTAGAGAATGGTGGGCT CTTAAGCCAGGAGCTCCACAACCAAAGGCTAATCAA CAACATCAAGATAATGCTAGAGGACTTGTTCTTCCA GGATATAAGTATCTTGGACCAGGAAATGGACTTGAT AAGGGAGAACCAGTTAATGCTGCTGATGCTGCTGCT CTTGAACATGATAAGGCTTATGATCAACAACTTAAG GCTGGAGATAATCCATATCTTAAGTATAATCATGCT GATGCTGAATTTCAAGAAAGACTTAAGGAAGATACT TCTTTTGGAGGAAATCTTGGAAGAGCTGTTTTTCAAG CTAAGAAGAGACTTCTTGAACCACTTGGACTTGTTG AAGAAGCTGCTAAGACGGCTCCAGGAAAGAAGAGA CCAGTTGAACAATCTCCACAAGAACCAGATTCTTCT GCTGGAATTGGAAAGTCTGGAGCTCAACCAGCTAAG AAGAGACTTAATTTCGGTCAGACTGGCGACACAGAG TCAGTCCCAGACCCTCAACCAATCGGAGAACCTCCC GCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCT TCAGGTGGTGGCGCACCAGTGGCAGACAATAACGA AGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCAATGGCTGGGGGACAGAGTCAT CACCACCAGCACCCGAACCTGGGCCCTGCCCACCTA CAACAATCACCTCTACAAGCAAATCTCCAACAGCAC ATCTGGAGGATCTTCAAATGACAACGCCTACTTCGG CTACAGCACCCCCTGGGGGTATTTTGACTTCAACAG ATTCCACTGCCACTTCTCACCACGTGACTGGCAGCG ACTCATCAACAACAACTGGGGATTCCGGCCTAAGCG ACTCAACTTCAAGCTCTTCAACATTCAGGTCAAAGA GGTTACGGACAACAATGGAGTCAAGACCATCGCCAA TAACCTTACCAGCACGGTCCAGGTCTTCACGGACTC AGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCA CGAGGGCTGCCTCCCGCCGTTCCCAGCGGACGTTTT CATGATTCCACAATATGGATATCTTACTCTTAATGAT GGATCTCAAGCTGTTGGAAGATCTTCTTTTTATTGTC TTGAATATTTTCCATCTCAAATGCTTAGAACTGGAAA TAATTTTCAATTTTCTTATGAATTTGAAAATGTTCCA TTTCATTCTTCTTATGCTCATTCTCAATCTCTTGATAG ACTTATGAATCCACTTATTGATCAATATCTTTATTAT CTTTCTAAGACTATTAATGGATCTGGACAAAATCAA CAAACTCTTAAGTTTTCTGTTGCTGGACCATCTAATA TGGCTGTTCAAGGAAGAAATTATATTCCAGGACCAT CTTATAGACAACAAAGAGTTTCTACTACTGTTACTCA AAATAATAATTCTGAATTTGCTTGGCCAGGAGCTTCT TCTTGGGCTCTTAATGGAAGAAATTCTCTTATGAATC CAGGACCAGCTATGGCTTCTCATAAGGAAGGAGAAG ATAGATTTTTTCCACTTTCTGGATCTCTTATTTTTGGA AAGCAAGGAACTGGAAGAGATAATGTTGATGCTGAT AAGGTTATGATTACTAATGAAGAAGAAATTAAGACT ACTAATCCAGTTGCTACTGAATCTTATGGACAAGTT GCTACTAATCATCAATCTGCTCAAGCTCAAGCTCAA ACTGGATGGGTTCAAAATCAAGGAATTCTTCCAGGAATGGTTTGGCAAGATAGAGATGTTTATCTTCAAGGA CCAATTTGGGCTAAGATTCCACATACTGATGGAAAT TTTCATCCATCTCCACTTATGGGAGGATTTGGAATGA AGCATCCACCACCACAAATTCTTATTAAGAATACTC CAGTTCCAGCTGATCCACCAACTGCTTTTAATAAGG ATAAGCTTAATTCTTTTATTACTCAATATTCTACTGG ACAAGTTTCTGTTGAAATTGAATGGGAACTTCAAAA GGAAAATTCTAAGAGATGGAATCCAGAAATTCAATA TACTTCTAATTATTATAAGTCTAATAATGTTGAATTT GCTGTTAATACTGAAGGAGTTTATTCTGAACCAAGA CCAATTGGAACTAGATATCTTACTAGAAATCTTRep2 FL optimized Coding ATGACTGGTTTCTACGAAATCGTTATTAAGGTTCCAT (SEQ ID NO: 4) CTGATTTGGATGGTCATCTTCCTGGAATCTCTGATTC ATTCGTTAACTGGGTTGCTGAAAAAGAGTGGGAATT GCCACCTGATTCAGATCTTGATTTGAATCTTATCGAA CAAGCTCCACTTACTGTTGCTGAGAAGTTGCAAAGA GATTTTCTTACAGAGTGGAGAAGGGTTTCTAAGGCT CCTGAGGCTCTTTTCTTTGTTCAATTCGAAAAGGGAG AGTCATACTTCCATTTGCATGTTCTTGTTGAAACTAC AGGTGTTAAGTCATTGGTTCTTGGAAGATTTTTGTCT CAAATCAGAGAAAAGCTTATCCAAAGAATCTATAGG GGTATTGAGCCAACTTTGCCTAATTGGTTTGCTGTTA CTAAGACAAGAAATGGTGCTGGAGGTGGAAATAAG GTTGTTGATGAATGTTACATCCCAAACTACCTTTTGC CAAAGACTCAACCTGAACTTCAATGGGCTTGGACAA ATTTGGAGCAATATCTTTCTGCTTGTTTGAATCTTAC AGAGAGAAAAAGGTTGGTTGCTCAACATCTTACTCA TGTTTCTCAAACACAAGAACAAAATAAGGAGAACCA AAACCCAAACTCAGATGCTCCTGTTATTAGATCAAA AACTTCTGCTAGGTACATGGAATTGGTTGGTTGGCTT GTTGATAAGGGAATTACATCTGAAAAACAGTGGATTCAAGAGGATCAAGCTTCATACATCTCTTTTAATGCTG CTTCTAACTCAAGATCTCAAATTAAGGCTGCTCTTGA TAATGCTGGAAAGATTATGTCATTGACTAAAACAGC TCCAGATTATCTTGTTGGACAACAACCTGTTGAAGA TATCTCTTCAAACAGAATCTATAAGATCTTGGAGCTT AATGGTTACGATCCACAATACGCTGCTTCTGTTTTTC TTGGTTGGGCTACTAAGAAATTCGGAAAGAGGAACA CAATTTGGCTTTTTGGTCCTGCTACTACAGGAAAAAC TAATATTGCTGAAGCTATTGCTCATACAGTTCCATTC TACGGTTGTGTTAACTGGACTAATGAGAACTTCCCTT TTAATGATTGTGTTGATAAGATGGTTATTTGGTGGGA AGAGGGAAAGATGACAGCTAAAGTTGTTGAATCAG CTAAGGCTATTTTGGGTGGATCTAAAGTTAGAGTTG ATCAAAAGTGTAAATCTTCAGCTCAAATTGATCCAA CTCCTGTTATTGTTACTTCAAACACAAACATGTGTGC TGTTATTGATGGTAACTCTACTACATTCGAACATCAA CAACCTCTTCAAGATAGGATGTTCAAGTTCGAGTTG ACTAGAAGGCTTGATCATGATTTTGGAAAGGTTACA AAGCAAGAGGTTAAGGATTTCTTTAGATGGGCTAAA GATCATGTTGTTGAGGTTGAACATGAGTTTTACGTTA AGAAAGGTGGAGCTAAGAAAAGGCCAGCTCCTTCA GATGCTGATATTTCTGAACCAAAGAGAGTTAGGGAG TCAGTTGCTCAACCTTCAACATCTGATGCTGAAGCTT CTATTAATTACGCTGATAGATACCAAAATAAGTGTT CAAGGCATGTTGGTATGAATTTGATGCTTTTTCCATG TAGACAATGTGAGAGGATGAATCAAAACTCTAACAT CTGTTTCACTCATGGACAAAAGGATTGTTTGGAATG TTTCCCAGTTTCAGAGTCTCAACCTGTTTCAGTTGTT AAGAAAGCTTACCAAAAGCTTTGTTACATCCATCAT ATCATGGGAAAAGTTCCTGATGCTTGTACAGCTTGTGATTTGGTTAATGTTGATCTTGATGATTGTATTTTTG AACAATAARep 52 optimized Coding ATGGAATTGGTTGGTTGGCTTGTTGATAAGGGAATT (SEQ ID NO: 5) ACATCTGAAAAACAGTGGATTCAAGAGGATCAAGCT TCATACATCTCTTTTAATGCTGCTTCTAACTCAAGAT CTCAAATTAAGGCTGCTCTTGATAATGCTGGAAAGA TTATGTCATTGACTAAAACAGCTCCAGATTATCTTGT TGGACAACAACCTGTTGAAGATATCTCTTCAAACAG AATCTATAAGATCTTGGAGCTTAATGGTTACGATCC ACAATACGCTGCTTCTGTTTTTCTTGGTTGGGCTACT AAGAAATTCGGAAAGAGGAACACAATTTGGCTTTTT GGTCCTGCTACTACAGGAAAAACTAATATTGCTGAA GCTATTGCTCATACAGTTCCATTCTACGGTTGTGTTA ACTGGACTAATGAGAACTTCCCTTTTAATGATTGTGT TGATAAGATGGTTATTTGGTGGGAAGAGGGAAAGAT GACAGCTAAAGTTGTTGAATCAGCTAAGGCTATTTT GGGTGGATCTAAAGTTAGAGTTGATCAAAAGTGTAA ATCTTCAGCTCAAATTGATCCAACTCCTGTTATTGTT ACTTCAAACACAAACATGTGTGCTGTTATTGATGGT AACTCTACTACATTCGAACATCAACAACCTCTTCAA GATAGGATGTTCAAGTTCGAGTTGACTAGAAGGCTT GATCATGATTTTGGAAAGGTTACAAAGCAAGAGGTT AAGGATTTCTTTAGATGGGCTAAAGATCATGTTGTT GAGGTTGAACATGAGTTTTACGTTAAGAAAGGTGGA GCTAAGAAAAGGCCAGCTCCTTCAGATGCTGATATT TCTGAACCAAAGAGAGTTAGGGAGTCAGTTGCTCAA CCTTCAACATCTGATGCTGAAGCTTCTATTAATTACG CTGATAGATACCAAAATAAGTGTTCAAGGCATGTTG GTATGAATTTGATGCTTTTTCCATGTAGACAATGTGA GAGGATGAATCAAAACTCTAACATCTGTTTCACTCA TGGACAAAAGGATTGTTTGGAATGTTTCCCAGTTTCAGAGTCTCAACCTGTTTCAGTTGTTAAGAAAGCTTA CCAAAAGCTTTGTTACATCCATCATATCATGGGAAA AGTTCCTGATGCTTGTACAGCTTGTGATTTGGTTAAT GTTGATCTTGATGATTGTATTTTTGAACAATAARep52 WT Coding ATGGAGCTGGTCGGGTGGCTCGTGGACAAGGGGATT (SEQ ID NO: 6) ACCTCGGAGAAGCAGTGGATCCAGGAGGACCAGGC CTCATACATCTCCTTCAATGCGGCCTCCAACTCGCGG TCCCAAATCAAGGCTGCCTTGGACAATGCGGGAAAG ATTATGAGCCTGACTAAAACCGCCCCCGACTACCTG GTGGGCCAGCAGCCCGTGGAGGACATTTCCAGCAAT CGGATTTATAAAATTTTGGAACTAAACGGGTACGAT CCCCAATATGCGGCTTCCGTCTTTCTGGGATGGGCCA CGAAAAAGTTCGGCAAGAGGAACACCATCTGGCTGT TTGGGCCTGCAACTACCGGGAAGACCAACATCGCGG AGGCCATAGCCCACACTGTGCCCTTCTACGGGTGCG TAAACTGGACCAATGAGAACTTTCCCTTCAACGACT GTGTCGACAAGATGGTGATCTGGTGGGAGGAGGGG AAGATGACCGCCAAGGTCGTGGAGTCGGCCAAAGC CATTCTCGGAGGAAGCAAGGTGCGCGTGGACCAGA AATGCAAGTCCTCGGCCCAGATAGACCCGACTCCCG TGATCGTCACCTCCAACACCAACATGTGCGCCGTGA TTGACGGGAACTCAACGACCTTCGAACACCAGCAGC CGTTGCAAGACCGGATGTTCAAATTTGAACTCACCC GCCGTCTGGATCATGACTTTGGGAAGGTCACCAAGC AGGAAGTCAAAGACTTTTTCCGGTGGGCAAAGGATC ACGTGGTTGAGGTGGAGCATGAATTCTACGTCAAAA AGGGTGGAGCCAAGAAAAGACCCGCCCCCAGTGAC GCAGATATAAGTGAGCCCAAACGGGTGCGCGAGTC AGTTGCGCAGCCATCGACGTCAGACGCGGAAGCTTC GATCAACTACGCGGACAGGTACCAAAACAAATGTTC TCGTCACGTGGGCATGAATCTGATGCTGTTTCCCTGCAGACAATGCGAGAGACTGAATCAGAATTCAAATATC TGCTTCACTCACGGTGTCAAAGACTGTTTAGAGTGCT TTCCCGTGTCAGAATCTCAACCCGTTTCTGTCGTCAA AAAGGCGTATCAGAAACTGTGCTACATTCATCACAT CATGGGAAAGGTGCCAGACGCTTGCACTGCTTGCGA CCTGGTCAATGTGGACTTGGATGACTGTGTTTCTGAA CAATAA WT start at VP2-ACG start ACGGCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCT Coding CCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAA (SEQ ID NO: 7) TCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTC GGTCAGACTGGCGACACAGAGTCAGTCCCAGACCCT CAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGT GTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCA CCAGTGGCAGACAATAACGAAGGTGCCGATGGAGT GGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCA ATGGCTGGGGGACAGAGTCATCACCACCAGCACCCG AACCTGGGCCCTGCCCACCTACAACAATCACCTCTA CAAGCAAATCTCCAACAGCACATCTGGAGGATCTTC AAATGACAACGCCTACTTCGGCTACAGCACCCCCTG GGGGTATTTTGACTTCAACAGATTCCACTGCCACTTC TCACCACGTGACTGGCAGCGACTCATCAACAACAAC TGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTC TTCAACATTCAGGTCAAAGAGGTTACGGACAACAAT GGAGTCAAGACCATCGCCAATAACCTTACCAGCACG GTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCG TACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCG CCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACG GGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGG GTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTC GCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAG CTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCC ACTCATCGACCAATACTTGTACTATCTCTCAAAGACT ATTAACGGTTCTGGACAGAATCAACAAACGCTAAAA TTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAG GGAAGAAACTACATACCTGGACCCAGCTACCGACAA CAACGTGTCTCAACCACTGTGACTCAAAACAACAAC AGCGAATTTGCTTGGCCTGGAGCTTCTTCTTGGGCTC TCAATGGACGTAATAGCTTGATGAATCCTGGACCTG CTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCT TTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGG AACTGGAAGAGACAACGTGGATGCGGACAAAGTCA TGATAACCAACGAAGAAGAAATTAAAACTACTAACC CGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAA ACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGC TGGGTTCAAAACCAAGGAATACTTCCGGGTATGGTT TGGCAGGACAGAGATGTGTACCTGCAAGGACCCATT TGGGCCAAAATTCCTCACACGGACGGCAACTTTCAC CCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCAC CCGCCTCCTCAGATCCTCATCAAAAACACACCTGTA CCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAG CTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAG TCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAA AACAGCAAGCGCTGGAACCCGGAGATCCAGTACACT TCCAACTATTACAAGTCTAATAATGTTGAATTTGCTG TTAATACTGAAGGTGTATATAGTGAACCCCGCCCCA TTGGCACCAGATACCTGACTCGTAATCTGTAA WT start at VP2-GTG start GTGGCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCT Coding CCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAA (SEQ ID NO: 8) TCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTC GGTCAGACTGGCGACACAGAGTCAGTCCCAGACCCT CAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCA CCAGTGGCAGACAATAACGAAGGTGCCGATGGAGT GGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCA ATGGCTGGGGGACAGAGTCATCACCACCAGCACCCG AACCTGGGCCCTGCCCACCTACAACAATCACCTCTA CAAGCAAATCTCCAACAGCACATCTGGAGGATCTTC AAATGACAACGCCTACTTCGGCTACAGCACCCCCTG GGGGTATTTTGACTTCAACAGATTCCACTGCCACTTC TCACCACGTGACTGGCAGCGACTCATCAACAACAAC TGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTC TTCAACATTCAGGTCAAAGAGGTTACGGACAACAAT GGAGTCAAGACCATCGCCAATAACCTTACCAGCACG GTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCG TACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCG CCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACG GGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGG GTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTC GCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAG CTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTA CGCTCACAGCCAAAGCCTGGACCGACTAATGAATCC ACTCATCGACCAATACTTGTACTATCTCTCAAAGACT ATTAACGGTTCTGGACAGAATCAACAAACGCTAAAA TTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAG GGAAGAAACTACATACCTGGACCCAGCTACCGACAA CAACGTGTCTCAACCACTGTGACTCAAAACAACAAC AGCGAATTTGCTTGGCCTGGAGCTTCTTCTTGGGCTC TCAATGGACGTAATAGCTTGATGAATCCTGGACCTG CTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCT TTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGG AACTGGAAGAGACAACGTGGATGCGGACAAAGTCA TGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAA ACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGC TGGGTTCAAAACCAAGGAATACTTCCGGGTATGGTT TGGCAGGACAGAGATGTGTACCTGCAAGGACCCATT TGGGCCAAAATTCCTCACACGGACGGCAACTTTCAC CCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCAC CCGCCTCCTCAGATCCTCATCAAAAACACACCTGTA CCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAG CTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAG TCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAA AACAGCAAGCGCTGGAACCCGGAGATCCAGTACACT TCCAACTATTACAAGTCTAATAATGTTGAATTTGCTG TTAATACTGAAGGTGTATATAGTGAACCCCGCCCCA TTGGCACCAGATACCTGACTCGTAATCTGTAA WT start at VP2-TTG start TTGGCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCT Coding CCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAA (SEQ ID NO: 9) TCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTC GGTCAGACTGGCGACACAGAGTCAGTCCCAGACCCT CAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGT GTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCA CCAGTGGCAGACAATAACGAAGGTGCCGATGGAGT GGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCA ATGGCTGGGGGACAGAGTCATCACCACCAGCACCCG AACCTGGGCCCTGCCCACCTACAACAATCACCTCTA CAAGCAAATCTCCAACAGCACATCTGGAGGATCTTC AAATGACAACGCCTACTTCGGCTACAGCACCCCCTG GGGGTATTTTGACTTCAACAGATTCCACTGCCACTTC TCACCACGTGACTGGCAGCGACTCATCAACAACAAC TGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTC TTCAACATTCAGGTCAAAGAGGTTACGGACAACAAT GGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCG TACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCG CCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACG GGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGG GTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTC GCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAG CTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTA CGCTCACAGCCAAAGCCTGGACCGACTAATGAATCC ACTCATCGACCAATACTTGTACTATCTCTCAAAGACT ATTAACGGTTCTGGACAGAATCAACAAACGCTAAAA TTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAG GGAAGAAACTACATACCTGGACCCAGCTACCGACAA CAACGTGTCTCAACCACTGTGACTCAAAACAACAAC AGCGAATTTGCTTGGCCTGGAGCTTCTTCTTGGGCTC TCAATGGACGTAATAGCTTGATGAATCCTGGACCTG CTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCT TTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGG AACTGGAAGAGACAACGTGGATGCGGACAAAGTCA TGATAACCAACGAAGAAGAAATTAAAACTACTAACC CGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAA ACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGC TGGGTTCAAAACCAAGGAATACTTCCGGGTATGGTT TGGCAGGACAGAGATGTGTACCTGCAAGGACCCATT TGGGCCAAAATTCCTCACACGGACGGCAACTTTCAC CCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCAC CCGCCTCCTCAGATCCTCATCAAAAACACACCTGTA CCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAG CTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAG TCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAA AACAGCAAGCGCTGGAACCCGGAGATCCAGTACACT TCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCA TTGGCACCAGATACCTGACTCGTAATCTGTAA WT FL all ATG start Coding ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAG (SEQ ID NO: 10) GACAACCTTAGTGAAGGAATTCGCGAGTGGTGGGCT TTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAA CAACATCAAGACAACGCTCGAGGTCTTGTGCTTCCG GGTTACAAATACCTTGGACCCGGCAACGGACTCGAC AAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGC CCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAA GGCCGGAGACAACCCGTACCTCAAGTACAACCACGC CGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATA CGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCC AGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGG TTGAGGAAGCGGCTAAGATGGCTCCTGGAAAGAAG AGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCC TCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCT AAAAAGAGACTCAATTTCGGTCAGACTGGCGACACA GAGTCAGTCCCAGACCCTCAACCAATCGGAGAACCT CCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATG GCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAAC GAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAAT TGGCATTGCGATTCCCAATGGCTGGGGGACAGAGTC ATCACCACCAGCACCCGAACCTGGGCCCTGCCCACC TACAACAATCACCTCTACAAGCAAATCTCCAACAGC ACATCTGGAGGATCTTCAAATGACAACGCCTACTTC GGCTACAGCACCCCCTGGGGGTATTTTGACTTCAAC AGATTCCACTGCCACTTCTCACCACGTGACTGGCAG CGACTCATCAACAACAACTGGGGATTCCGGCCTAAG CGACTCAACTTCAAGCTCTTCAACATTCAGGTCAAA GAGGTTACGGACAACAATGGAGTCAAGACCATCGCC AATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCT CACGAGGGCTGCCTCCCGCCGTTCCCAGCGGACGTT TTCATGATTCCTCAGTACGGGTATCTGACGCTTAATG ATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACT GCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGG GTAACAACTTCCAGTTCAGCTACGAGTTTGAGAACG TACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCC TGGACCGACTAATGAATCCACTCATCGACCAATACT TGTACTATCTCTCAAAGACTATTAACGGTTCTGGACA GAATCAACAAACGCTAAAATTCAGTGTGGCCGGACC CAGCAACATGGCTGTCCAGGGAAGAAACTACATACC TGGACCCAGCTACCGACAACAACGTGTCTCAACCAC TGTGACTCAAAACAACAACAGCGAATTTGCTTGGCC TGGAGCTTCTTCTTGGGCTCTCAATGGACGTAATAGC TTGATGAATCCTGGACCTGCTATGGCCAGCCACAAA GAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTT TAATTTTTGGCAAACAAGGAACTGGAAGAGACAACG TGGATGCGGACAAAGTCATGATAACCAACGAAGAA GAAATTAAAACTACTAACCCGGTAGCAACGGAGTCC TATGGACAAGTGGCCACAAACCACCAGAGTGCCCAA GCACAGGCGCAGACCGGCTGGGTTCAAAACCAAGG AATACTTCCGGGTATGGTTTGGCAGGACAGAGATGT GTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCA CACGGACGGCAACTTTCACCCTTCTCCGCTGATGGG AGGGTTTGGAATGAAGCACCCGCCTCCTCAGATCCT CATCAAAAACACACCTGTACCTGCGGATCCTCCAAC GGCCTTCAACAAGGACAAGCTGAACTCTTTCATCAC CCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGA GTGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGA ACCCGGAGATCCAGTACACTTCCAACTATTACAAGT CTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCT GACTCGTAATCTGTAA WT FL VP1 ACG start ACGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAG Coding GACAACCTTAGTGAAGGAATTCGCGAGTGGTGGGCT (SEQ ID NO: 11) TTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAA CAACATCAAGACAACGCTCGAGGTCTTGTGCTTCCG GGTTACAAATACCTTGGACCCGGCAACGGACTCGAC AAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGC CCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAA GGCCGGAGACAACCCGTACCTCAAGTACAACCACGC CGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATA CGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCC AGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGG TTGAGGAAGCGGCTAAGACGGCTCCTGGAAAGAAG AGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCC TCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCT AAAAAGAGACTCAATTTCGGTCAGACTGGCGACACA GAGTCAGTCCCAGACCCTCAACCAATCGGAGAACCT CCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATG GCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAAC GAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAAT TGGCATTGCGATTCCCAATGGCTGGGGGACAGAGTC ATCACCACCAGCACCCGAACCTGGGCCCTGCCCACC TACAACAATCACCTCTACAAGCAAATCTCCAACAGC ACATCTGGAGGATCTTCAAATGACAACGCCTACTTC GGCTACAGCACCCCCTGGGGGTATTTTGACTTCAAC AGATTCCACTGCCACTTCTCACCACGTGACTGGCAG CGACTCATCAACAACAACTGGGGATTCCGGCCTAAG CGACTCAACTTCAAGCTCTTCAACATTCAGGTCAAA GAGGTTACGGACAACAATGGAGTCAAGACCATCGCC AATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCT CACGAGGGCTGCCTCCCGCCGTTCCCAGCGGACGTT TTCATGATTCCTCAGTACGGGTATCTGACGCTTAATG ATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACT GCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGG GTAACAACTTCCAGTTCAGCTACGAGTTTGAGAACG TACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCC TGGACCGACTAATGAATCCACTCATCGACCAATACT TGTACTATCTCTCAAAGACTATTAACGGTTCTGGACA GAATCAACAAACGCTAAAATTCAGTGTGGCCGGACC CAGCAACATGGCTGTCCAGGGAAGAAACTACATACC TGGACCCAGCTACCGACAACAACGTGTCTCAACCAC TGTGACTCAAAACAACAACAGCGAATTTGCTTGGCC TGGAGCTTCTTCTTGGGCTCTCAATGGACGTAATAGC TTGATGAATCCTGGACCTGCTATGGCCAGCCACAAA GAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTT TAATTTTTGGCAAACAAGGAACTGGAAGAGACAACG TGGATGCGGACAAAGTCATGATAACCAACGAAGAA GAAATTAAAACTACTAACCCGGTAGCAACGGAGTCC TATGGACAAGTGGCCACAAACCACCAGAGTGCCCAA GCACAGGCGCAGACCGGCTGGGTTCAAAACCAAGG AATACTTCCGGGTATGGTTTGGCAGGACAGAGATGT GTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCA CACGGACGGCAACTTTCACCCTTCTCCGCTGATGGG AGGGTTTGGAATGAAGCACCCGCCTCCTCAGATCCT CATCAAAAACACACCTGTACCTGCGGATCCTCCAAC GGCCTTCAACAAGGACAAGCTGAACTCTTTCATCAC CCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGA GTGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGA ACCCGGAGATCCAGTACACTTCCAACTATTACAAGT CTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCT GACTCGTAATCTGTAA WT VP3 Coding ATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAAT (SEQ ID NO: 12) AACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGA AATTGGCATTGCGATTCCCAATGGCTGGGGGACAGA GTCATCACCACCAGCACCCGAACCTGGGCCCTGCCC ACCTACAACAATCACCTCTACAAGCAAATCTCCAAC AGCACATCTGGAGGATCTTCAAATGACAACGCCTAC TTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTCA ACAGATTCCACTGCCACTTCTCACCACGTGACTGGC AGCGACTCATCAACAACAACTGGGGATTCCGGCCTA AGCGACTCAACTTCAAGCTCTTCAACATTCAGGTCA AAGAGGTTACGGACAACAATGGAGTCAAGACCATC GCCAATAACCTTACCAGCACGGTCCAGGTCTTCACG GACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCG GCTCACGAGGGCTGCCTCCCGCCGTTCCCAGCGGAC GTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTA ATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTT ACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAA CGGGTAACAACTTCCAGTTCAGCTACGAGTTTGAGA ACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAA GCCTGGACCGACTAATGAATCCACTCATCGACCAAT ACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGG ACAGAATCAACAAACGCTAAAATTCAGTGTGGCCGG ACCCAGCAACATGGCTGTCCAGGGAAGAAACTACAT ACCTGGACCCAGCTACCGACAACAACGTGTCTCAAC CACTGTGACTCAAAACAACAACAGCGAATTTGCTTG GCCTGGAGCTTCTTCTTGGGCTCTCAATGGACGTAAT AGCTTGATGAATCCTGGACCTGCTATGGCCAGCCAC AAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGA TCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGTGGATGCGGACAAAGTCATGATAACCAACGA AGAAGAAATTAAAACTACTAACCCGGTAGCAACGG AGTCCTATGGACAAGTGGCCACAAACCACCAGAGTG CCCAAGCACAGGCGCAGACCGGCTGGGTTCAAAACC AAGGAATACTTCCGGGTATGGTTTGGCAGGACAGAG ATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTC CTCACACGGACGGCAACTTTCACCCTTCTCCGCTGAT GGGAGGGTTTGGAATGAAGCACCCGCCTCCTCAGAT CCTCATCAAAAACACACCTGTACCTGCGGATCCTCC AACGGCCTTCAACAAGGACAAGCTGAACTCTTTCAT CACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGAT CGAGTGGGAGCTGCAGAAGGAAAACAGCAAGCGCT GGAACCCGGAGATCCAGTACACTTCCAACTATTACA AGTCTAATAATGTTGAATTTGCTGTTAATACTGAAG GTGTATATAGTGAACCCCGCCCCATTGGCACCAGAT ACCTGACTCGTAATCTGTAACodon optimized TCP8 ATGGAAACTAAGCCTAAGACCGCTACTACCATCAAG Coding GTTCCACCTGGTCCTCTTGGTTACGTTTACGCTAGAG (SEQ ID NO: 13) CTTGTCCGTCTGAGGGTATCGAGCTTCTTGCTCTGCT TAGCGCTAGGTCCGGTGATGCTGATGTTGCTGTTGCT CCTCTTGTGGTGGGTCTTACTGTTGAGTCTGGCTTCG AGGCTAATGTGGCTGTTGTTGTTGGTTCTAGGACCAC CGGACTTGGTGGTACTGCTGTGTCTCTTAAGTTGACC CCGAGCCACTACAGCAGCTCCGTTTATGTTTTTCACG GTGGCAGGCACCTCGATCCTTCTACTCAAGCTCCTA ACCTTACCAGGCTTTGTGAGAGGGCTAGAAGGCACT TCGGCTTCTCTGATTACACTCCTAGGCCAGGTGATCT GAAGCACGAAACTACTGGTGAGGCTCTTTGCGAGAG GCTTGGTCTTGATCCTGATAGGGCTCTGCTTTACCTT GTGGTGACCGAGGGTTTCAAAGAGGCTGTCTGCATC AACAACACCTTTCTGCACCTTGGCGGCTCTGATAAGGTTACCATTGGTGGTGCTGAGGTGCACAGGATTCCA GTTTATCCTCTCCAGCTGTTCATGCCGGATTTCTCTA GGGTTATCGCTGAGCCTTTCAACGCCAACCACAGAT CTATCGGCGAGAACTTCACTTACCCTCTGCCGTTCTT CAACCGGCCTCTTAACAGGCTTTTGTTCGAGGCAGTT GTTGGTCCTGCTGCTGTTGCACTTAGGTGCCGTAATG TTGATGCTGTGGCTAGAGCTGCTGCTCACCTTGCTTT CGATGAGAATCATGAGGGTGCTGCTCTGCCTGCTGA TATTACTTTCACTGCTTTCGAGGCCAGCCAGGGTAA GACTCCTAGAGGTGGTAGAGATGGTGGTGGTAAGGG ACCTGCTGGTGGTTTTGAACAGAGGCTTGCTTCTGTG ATGGCTGGGGATGCTGCTCTTGCTCTTGAGTCTATTG TGAGCATGGCTGTGTTCGATGAGCCTCCTACCGATA TTTCTGCTTGGCCTCTTTGTGAAGGCCAGGATACTGC TGCTGCTAGGGCTAATGCTGTTGGTGCTTATCTTGCT CGTGCTGCTGGTCTTGTTGGAGCTATGGTGTTCTCTA CCAACAGCGCTCTGCATCTTACTGAGGTTGACGATG CTGGTCCAGCTGATCCAAAGGATCACAGCAAGCCGA GCTTCTACAGATTCTTCCTTGTGCCTGGTACTCACGT GGCAGCTAATCCTCAAGTGGATCGTGAAGGTCATGT GGTGCCTGGTTTTGAGGGTAGACCTACTGCTCCTTTG GTTGGTGGAACTCAAGAGTTCGCTGGTGAGCACCTT GCTATGCTTTGCGGTTTTTCTCCTGCTCTGCTGGCCA AGATGCTGTTCTATCTTGAGAGGTGTGATGGCGGTG TGATCGTTGGTAGACAAGAGATGGACGTGTTCCGGT ACGTGGCAGATTCTAATCAGACTGACGTGCCATGCA ACTTGTGCACCTTCGATACAAGGCATGCTTGCGTGC ACACTACCCTTATGAGACTTAGAGCTAGGCACCCGA AGTTCGCTTCAGCTGCTAGAGGTGCTATTGGTGTGTT CGGCACCATGAACTCCATGTACTCCGACTGTGATGT CCTGGGAAACTACGCTGCTTTCAGCGCTCTTAAGCGTGCTGATGGTTCTGAGACTGCTCGGACCATTATGCA AGAGACTTACAGGGCTGCTACCGAGAGAGTTATGGC TGAGCTTGAGACTCTTCAGTACGTTGACCAGGCTGT GCCTACTGCTATGGGTAGACTTGAGACTATCATCAC CAACAGAGAGGCCCTTCACACCGTTGTGAACAATGT TAGGCAGGTTGTGGACCGTGAGGTTGAGCAGCTTAT GAGGAATCTTGTTGAGGGCCGTAACTTCAAGTTCAG AGATGGTCTTGGAGAGGCCAACCACGCTATGTCTCT TACCCTTGATCCTTACGCTTGCGGTCCTTGTCCTCTG CTTCAACTTCTTGGTCGGAGGTCTAACTTGGCTGTGT ACCAGGATCTTGCCCTTTCTCAGTGCCACGGTGTTTT TGCTGGTCAGTCTGTGGAAGGTCGGAACTTCAGAAA TCAGTTCCAGCCTGTGCTTCGGAGGCGTGTGATGGA TATGTTCAACAACGGATTCCTGAGCGCTAAGACCCT TACCGTTGCTCTTTCTGAGGGTGCAGCTATTTGCGCT CCTTCTCTTACTGCTGGTCAAACCGCTCCTGCTGAGT CATCATTTGAGGGTGATGTTGCAAGGGTGACCCTGG GTTTTCCTAAAGAGCTGAGGGTTAAGAGCAGGGTGC TGTTTGCTGGTGCTTCTGCTAATGCTTCAGAGGCTGC TAAGGCTAGGGTTGCCTCTCTTCAATCTGCTTACCAG AAGCCGGATAAGCGGGTTGACATTCTTCTTGGCCCT CTGGGTTTCCTGCTGAAGCAATTCCATGCTGCTATCT TCCCTAACGGTAAGCCTCCTGGAAGCAACCAGCCTA ATCCACAGTGGTTTTGGACTGCCCTTCAGAGGAATC AGCTTCCTGCTAGGCTTCTGAGCAGAGAGGATATCG AGACTATCGCCTTTATCAAGAAATTCAGCCTGGACT ACGGCGCCATCAACTTCATTAACCTGGCTCCGAACA ACGTGAGCGAGCTGGCTATGTACTACATGGCTAACC AGATCCTGAGGTACTGCGACCACTCTACCTACTTCAT CAACACCCTGACCGCTATTATCGCTGGATCAAGAAG GCCACCTTCTGTTCAGGCAGCTGCTGCATGGTCTGCTCAAGGTGGTGCAGGTCTTGAAGCTGGTGCTAGAGCA CTTATGGATGCTGTTGACGCTCATCCTGGTGCTTGGA CTTCTATGTTCGCTTCCTGCAACCTTCTGAGGCCAGT TATGGCAGCTAGGCCAATGGTTGTGCTTGGGCTGAG CATCAGCAAGTATTACGGTATGGCTGGCAACGACAG GGTTTTCCAAGCTGGTAATTGGGCTTCCCTGATGGGT GGTAAGAATGCTTGCCCTCTGCTGATCTTCGACAGG ACCAGAAAGTTCGTTCTGGCTTGTCCTAGAGCTGGTT TCGTTTGCGCTGCTAGTTCTCTTGGAGGTGGTGCTCA TGAGAGTTCTTTGTGCGAACAGCTGAGGGGCATTAT CTCTGAAGGTGGCGCAGCTGTTGCTTCTTCTGTTTTC GTTGCTACCGTGAAGTCCCTCGGACCTAGAACTCAG CAGCTTCAGATTGAGGATTGGCTCGCTCTTTTGGAG GACGAGTACCTGTCTGAAGAGATGATGGAACTTACC GCTAGGGCTCTTGAGCGTGGTAATGGTGAATGGTCT ACCGATGCTGCTTTGGAGGTTGCACATGAGGCTGAG GCTTTGGTTTCTCAGCTTGGTAATGCTGGCGAGGTGT TCAACTTCGGTGATTTCGGTTGCGAGGATGACAACG CTACTCCTTTTGGTGGACCTGGTGCTCCTGGACCTGC TTTTGCTGGAAGAAAAAGGGCTTTCCACGGCGGCGA TCCTTTTGGAGAAGGTCCTCCTGATAAGAAGGGCGA TCTGACCCTTGATATGCTGTAGCodon optimized UL30 ATGTTCTCTGGTGGTGGTGGACCTTTGTCTCCTGGTG Coding GTAAGTCTGCTGCTAGAGCTGCTTCTGGTTTCTTTGC (SEQ ID NO: 14) TCCTGCTGGTCCTAGAGGTGCTAGTAGAGGTCCTCC ACCTTGTCTTAGGCAGAACTTCTACAACCCTTACCTG GCTCCTGTTGGAACTCAGCAAAAGCCTACTGGTCCT ACTCAGAGGCACACCTACTACTCTGAGTGTGACGAG TTCCGGTTCATTGCTCCTAGAGTGCTTGATGAGGATG CTCCTCCTGAAAAGCGTGCTGGTGTTCATGATGGTC ACCTTAAGAGGGCTCCTAAGGTTTACTGTGGTGGGGATGAGAGGGATGTGCTGAGAGTTGGTTCTGGTGGTT TTTGGCCTAGAAGGTCTAGGCTTTGGGGTGGTGTTG ATCATGCTCCAGCTGGTTTCAATCCTACCGTGACTGT GTTCCACGTGTACGACATTCTTGAGAACGTCGAGCA CGCTTACGGTATGAGAGCTGCTCAATTCCACGCTCG GTTCATGGATGCTATTACTCCTACCGGAACCGTGATT ACCCTTCTTGGTCTTACTCCTGAGGGTCACAGAGTTG CTGTTCATGTGTATGGCACCCGGCAGTATTTCTACAT GAACAAAGAAGAGGTGGACCGGCACCTTCAATGTA GGGCTCCAAGAGATCTTTGCGAGAGAATGGCTGCTG CTCTGAGAGAAAGTCCTGGTGCTTCTTTCAGGGGCA TCTCTGCTGATCATTTCGAGGCTGAAGTGGTCGAGA GGACCGATGTTTACTACTACGAGACTAGGCCGGCTC TGTTCTACAGGGTTTACGTTAGGTCTGGTCGGGTGCT GTCTTACCTGTGCGATAATTTCTGCCCGGCCATCAAG AAGTACGAAGGCGGAGTTGATGCTACCACCAGATTC ATCCTTGACAACCCTGGTTTCGTGACCTTCGGTTGGT ACAGACTTAAGCCCGGTAGGAACAATACCCTTGCTC AACCTAGAGCACCTATGGCTTTCGGGACTAGCTCCG ATGTTGAGTTCAACTGCACCGCTGATAACCTGGCTA TCGAAGGCGGTATGTCTGATCTGCCTGCTTACAAGC TGATGTGCTTCGACATTGAGTGCAAGGCTGGTGGTG AAGATGAGCTTGCTTTTCCTGTTGCTGGTCACCCTGA GGATCTTGTGATCCAGATTTCTTGCCTGCTGTACGAC CTTTCTACCACCGCTCTTGAGCACGTTCTGCTTTTCT CACTTGGCTCTTGCGATCTCCCTGAGTCTCACCTTAA TGAGTTGGCTGCTAGGGGTTTGCCTACTCCTGTTGTG CTTGAGTTCGACAGCGAGTTCGAGATGCTGCTTGCTT TCATGACCCTGGTGAAGCAGTACGGTCCTGAGTTCG TGACCGGCTACAACATCATCAACTTCGACTGGCCTTT CCTGCTGGCTAAGCTGACCGATATCTACAAGGTGCCACTGGATGGTTACGGCAGGATGAATGGTAGGGGAGT GTTCAGAGTTTGGGACATCGGTCAGTCTCACTTCCA GAAGCGGAGCAAGATCAAGGTGAACGGCATGGTGA ACATCGACATGTACGGCATCATCACCGATAAGATCA AGCTGTCCAGCTACAAGCTCAACGCTGTTGCTGAGG CTGTGCTGAAGGATAAGAAGAAGGACCTGAGCTAC AGGGACATCCCTGCTTATTATGCTGCTGGACCTGCTC AGAGGGGTGTGATTGGTGAATACTGTATCCAGGACT CTCTGCTGGTTGGCCAGCTGTTCTTTAAGTTCTTGCC TCACCTTGAGCTGAGCGCTGTTGCAAGACTTGCTGG TATTAACATCACCCGGACCATCTACGATGGCCAGCA GATTAGAGTGTTCACATGCCTTCTCAGGCTGGCTGAT CAGAAGGGTTTCATTCTGCCTGATACTCAGGGCAGA TTCAGAGGTGCTGGTGGCGAAGCTCCTAAAAGACCT GCTGCTGCAAGAGAGGATGAGGAAAGACCTGAAGA GGAAGGTGAGGACGAGGACGAACGTGAAGAAGGTG GCGGAGAAAGGGAACCTGAAGGTGCTAGAGAAACT GCTGGTAGGCATGTTGGATACCAGGGCGCAAGAGTT CTTGATCCTACCTCTGGTTTCCACGTGAACCCTGTTG TGGTGTTCGATTTCGCTTCTCTGTACCCGTCTATCAT CCAGGCTCACAACCTGTGCTTCTCTACCTTGTCTCTT AGGGCTGATGCTGTGGCTCATCTTGAGGCTGGTAAG GACTACCTTGAGATTGAGGTTGGAGGCAGGCGGTTG TTCTTCGTTAAGGCTCATGTGAGAGAGAGCCTGCTG TCTATCCTTCTGAGAGATTGGCTGGCCATGAGGAAG CAGATCAGGTCTAGGATTCCTCAGTCCAGTCCTGAG GAAGCTGTGCTGCTTGATAAGCAACAGGCTGCTATT AAGGTGGTGTGCAACTCCGTGTACGGTTTCACAGGT GTTCAGCACGGTTTGCTGCCATGCCTTCATGTTGCTG CTACTGTGACCACTATCGGCAGAGAGATGCTTTTGG CTACCAGGGAATATGTGCATGCTAGGTGGGCTGCTTTCGAGCAGCTTCTTGCTGATTTTCCTGAGGCTGCTGA TATGAGAGCACCTGGGCCTTATAGCATGAGGATCAT CTACGGCGATACCGACTCTATCTTCGTGTTGTGCAGA GGTCTTACCGCTGCTGGTTTGACTGCTGTGGGTGATA AGATGGCCTCTCACATTAGCAGGGCTCTGTTTCTGCC TCCGATTAAGTTGGAGTGCGAAAAGACCTTCACCAA GCTGCTGCTGATCGCCAAGAAGAAGTACATCGGCGT TATCTACGGTGGCAAGATGCTGATCAAGGGTGTTGA CCTGGTGCGTAAGAACAACTGCGCTTTCATCAACAG GACCTCCAGGGCTCTTGTGGATCTGCTGTTCTACGAT GATACCGTGTCTGGTGCAGCTGCTGCATTGGCTGAA AGACCAGCTGAAGAATGGCTTGCTAGACCTTTGCCT GAGGGACTTCAGGCTTTTGGTGCTGTGCTTGTGGAT GCTCACAGAAGGATTACTGATCCCGAGCGGGATATC CAGGATTTCGTTCTTACTGCTGAGCTGTCTAGGCACC CTAGGGCTTACACTAACAAGAGGCTTGCTCACCTGA CCGTGTACTACAAGTTGATGGCTAGAAGGGCTCAAG TGCCCAGCATCAAGGACAGGATTCCTTACGTTATCG TGGCTCAGACCAGAGAGGTGGAAGAGACTGTTGCTA GATTGGCAGCTCTGCGTGAGTTGGATGCTGCTGCCC CTGGTGATGAACCTGCTCCTCCAGCTGCTTTGCCTTC TCCAGCTAAGAGGCCAAGAGAAACTCCTTCTCCTGC TGATCCACCTGGTGGTGCTTCAAAGCCAAGAAAGTT GCTTGTGAGCGAGCTTGCTGAGGACCCTGCTTACGC TATTGCTCATGGTGTGGCTCTCAACACCGACTACTAC TTCTCTCACCTTCTGGGAGCTGCTTGCGTTACCTTCA AGGCTCTTTTCGGCAACAACGCCAAGATCACCGAGT CTCTGCTTAAGCGGTTCATTCCTGAGGTTTGGCACCC TCCAGATGATGTGGCAGCTAGACTTAGGACTGCTGG ATTTGGAGCTGTTGGTGCTGGCGCTACTGCTGAAGAAACTAGAAGGATGCTTCACCGGGCTTTCGATACCTT GGCTTAGCodon optimized UL42 ATGACCGATTCTCCTGGTGGTGTTGCTCCTGCTTCTC Coding ATGTTGAGGATGCTTCCGATGCTTCTCTTGGTCAGCC (SEQ ID NO: 15) TGAAGAAGGTGCTCCTTGTCAAGTTGTTCTTCAGGGT GCTGAGCTGAACGGTATCCTTCAGGCTTTTGCTCCTC TTAGGACCAGCCTTCTTGATAGCCTTCTGGTGATGGG TGATCGTGGTATCCTTATCCACAACACCATCTTCGGC GAGCAGGTTTTCTTGCCTCTTGAGCACTCTCAGTTCA GCAGGTATAGATGGTCTGGTCCTACCGCTGCTTTCCT GTCTCTTGTTGATCAGAAGCGGAGCCTGCTTTCTGTG TTCAGGGCTAATCAGTACCCTGATCTGAGAAGGGTT GAGCTGGCTATTACTGGTCAGGCTCCTTTCAGGACTC TTGTGCAGAGGATTTGGACCACCACTTCTGATGGTG AGGCTGTCGAACTTGCTTCCGAGACTCTTATGAAGC GTGAGCTGACTTCTTTCGTGGTGCTTGTTCCTCAGGG AACTCCTGATGTTCAGCTGAGGCTTACTAGGCCACA GCTTACCAAGGTGTTGAACGCTACTGGTGCTGATTCT GCTACTCCTACCACTTTCGAGCTTGGTGTGAACGGC AAGTTCTCAGTGTTCACCACCTCTACTTGCGTGACCT TCGCTGCTAGAGAAGAGGGTGTGAGTAGCTCTACTT CTACCCAGGTGCAGATCCTGTCTAACGCTCTTACTAA GGCTGGACAGGCTGCTGCTAATGCTAAGACTGTGTA CGGTGAGAATACCCACAGGACCTTCTCTGTTGTGGT GGACGATTGCTCTATGAGGGCTGTGCTTAGAAGGCT TCAGGTTGGAGGTGGAACCCTGAAGTTCTTCCTTACT ACTCCTGTGCCGTCTTTGTGCGTGACAGCTACTGGAC CTAATGCTGTGTCTGCTGTGTTCCTTCTGAAGCCGCA GAAGATTTGCCTGGATTGGCTTGGTCATAGCCAGGG TTCTCCATCTGCTGGTTCTTCAGCTTCAAGAGCTTCT GGTTCTGAGCCTACCGACTCTCAGGATTCTGCTTCTGATGCTGTTAGCCACGGTGATCCTGAGGATCTTGATG GTGCTGCAAGAGCTGGTGAAGCTGGTGCTTCTTATG CTTGCCCTATGCCATCTTCTACTACCAGGGTTACCCC TACTACTAAGCGTGGTAGGTCTGGTGGTGAAGATGC TAGAGCTGATACCGCTCTGAAGAAGCCTAAGACTGG TTCTCCTACTGCTCCTCCTCCTGCTGATCCTGTTCCTC TTGATACCGAGGATGATAGCGACGCTGCTGATGGTA CTGCTGCTAGACCTGCTGCTCCAGATGCTAGGTCTG GATCTAGGTACGCTTGCTACTTCAGGGATCTTCCTAC AGGTGAAGCTAGTCCTGGTGCTTTCTCTGCTTTTAGA GGTGGACCTCAGACTCCTTACGGTTTCGGTTTTCCTT AACodon optimized Ad5E4orf6 ATGACTACATCTGGTGTTCCATTTGGAATGACTCTTA Coding GACCTACAAGATCTAGGTTGTCAAGAAGGACACCAT (SEQ ID NO: 16) ATTCAAGAGATAGGCTTCCACCTTTTGAAACTGAGA CAAGGGCTACTATTTTGGAAGATCATCCACTTTTGCC TGAGTGTAATACTCTTACAATGCATAATGCTTGGAC ATCTCCTTCACCACCTGTTAAGCAACCACAAGTTGGT CAACAACCTGTTGCTCAACAATTGGATTCTGATATG AATCTTTCAGAATTGCCAGGAGAGTTTATTAATATC ACTGATGAAAGACTTGCTAGGCAAGAGACTGTTTGG AACATCACACCTAAGAACATGTCTGTTACTCATGAT ATGATGTTGTTTAAAGCTTCTAGAGGTGAAAGGACA GTTTACTCAGTTTGTTGGGAGGGAGGTGGAAGACTT AATACTAGGGTTTTGTAACodon optimized AAP2-S2 TTAGAGACTCAGACACAATACTTGACTCCATCACTTT Coding CAGATAGCCATCAGCAGCCTCCACTCGTTTGGGAAC (SEQ ID NO: 17) TCATAAGGTGGCTTCAAGCTGTTGCTCATCAATGGC AAACAATTACTAGGGCTCCTACAGAATGGGTTATTC CAAGAGAGATTGGAATTGCTATTCCTCATGGTTGGG CTACTGAATCTTCACCACCTGCTCCAGAGCCTGGACCATGTCCACCTACTACAACTACATCAACAAATAAGT TTCCTGCTAATCAAGAACCAAGAACTACAATTACTA CACTTGCTACTGCTCCTCTTGGAGGTATTTTGACATC AACTGATTCTACAGCTACTTTTCATCATGTTACAGGA AAAGATTCTTCAACTACAACTGGAGATTCAGATCCA AGGGATTCTACATCTTCATCTTTGACTTTTAAGTCAA AAAGATCTAGAAGGATGACAGTTAGAAGGAGACTT CCTATTACTTTGCCAGCTAGGTTTAGATGTCTTTTGA CAAGGTCTACTTCATCTAGAACTTCATCTGCTAGGA GAATTAAGGATGCAAGCAGAAGAAGCCAACAGACA AGTTCCTGGTGCCACAGCATGGATACAAGCCCTTAA WT E2A Coding ATGGCCAGTCGGGAAGAGGAGCAGCGCGAAACCAC (SEQ ID NO: 18) CCCCGAGCGCGGACGCGGTGCGGCGCGACGTCCCCC AACCATGGAGGACGTGTCGTCCCCGTCCCCGTCGCC GCCGCCTCCCCGGGCGCCCCCAAAAAAGCGGATGAG GCGGCGTATCGAGTCCGAGGACGAGGAAGACTCATC ACAAGACGCGCTGGTGCCGCGCACACCCAGCCCGCG GCCATCGACCTCGGCGGCGGATTTGGCCATTGCGCC CAAGAAGAAAAAGAAGCGCCCTTCTCCCAAGCCCG AGCGCCCGCCATCACCAGAGGTAATCGTGGACAGCG AGGAAGAAAGAGAAGATGTGGCGCTACAAATGGTG GGTTTCAGCAACCCACCGGTGCTAATCAAGCATGGC AAAGGAGGTAAGCGCACAGTGCGGCGGCTGAATGA AGACGACCCAGTGGCGCGTGGTATGCGGACGCAAG AGGAAGAGGAAGAGCCCAGCGAAGCGGAAAGTGAA ATTACGGTGATGAACCCGCTGAGTGTGCCGATCGTG TCTGCGTGGGAGAAGGGCATGGAGGCTGCGCGCGC GCTGATGGACAAGTACCACGTGGATAACGATCTAAA GGCGAACTTCAAACTACTGCCTGACCAAGTGGAAGC TCTGGCGGCCGTATGCAAGACCTGGCTGAACGAGGA GCACCGCGGGTTGCAGCTGACCTTCACCAGCAACAAGACCTTTGTGACGATGATGGGGCGATTCCTGCAGGC GTACCTGCAGTCGTTTGCAGAGGTGACCTACAAGCA TCACGAGCCCACGGGCTGCGCGTTGTGGCTGCACCG CTGCGCTGAGATCGAAGGCGAGCTTAAGTGTCTACA CGGAAGCATTATGATAAATAAGGAGCACGTGATTGA AATGGATGTGACGAGCGAAAACGGGCAGCGCGCGC TGAAGGAGCAGTCTAGCAAGGCCAAGATCGTGAAG AACCGGTGGGGCCGAAATGTGGTGCAGATCTCCAAC ACCGACGCAAGGTGCTGCGTGCACGACGCGGCCTGT CCGGCCAATCAGTTTTCCGGCAAGTCTTGCGGCATG TTCTTCTCTGAAGGCGCAAAGGCTCAGGTGGCTTTTA AGCAGATCAAGGCTTTTATGCAGGCGCTGTATCCTA ACGCCCAGACCGGGCACGGTCACCTTTTGATGCCAC TACGGTGCGAGTGCAACTCAAAGCCTGGGCACGCGC CCTTTTTGGGAAGGCAGCTACCAAAGTTGACTCCGT TCGCCCTGAGCAACGCGGAGGACCTGGACGCGGATC TGATCTCCGACAAGAGCGTGCTGGCCAGCGTGCACC ACCCGGCGCTGATAGTGTTCCAGTGCTGCAACCCTG TGTATCGCAACTCGCGCGCGCAGGGCGGAGGCCCCA ACTGCGACTTCAAGATATCGGCGCCCGACCTGCTAA ACGCGTTGGTGATGGTGCGCAGCCTGTGGAGTGAAA ACTTCACCGAGCTGCCGCGGATGGTTGTGCCTGAGT TTAAGTGGAGCACTAAACACCAGTATCGCAACGTGT CCCTGCCAGTGGCGCATAGCGATGCGCGGCAGAACC CCTTTGATTTTTAACodon optimized E2A Coding ATGGCCAGCCGTGAAGAGGAACAGAGAGAAACTAC (SEQ ID NO: 19) TCCTGAGAGAGGTAGGGGAGCTGCTAGAAGGCCTCC TACTATGGAAGATGTGTCCTCTCCATCTCCTAGTCCT CCGCCTCCTAGGGCTCCTCCTAAGAAAAGAATGAGG CGTAGGATCGAGAGCGAGGACGAAGAGGATTCTTCT CAGGATGCTCTTGTGCCGAGAACACCTTCTCCTAGGCCTTCAACTTCTGCTGCTGATCTTGCTATCGCCCCAA AGAAGAAGAAAAAGCGGCCTTCTCCAAAGCCTGAG AGGCCTCCTTCACCTGAGGTTATCGTTGACAGCGAA GAGGAACGTGAGGATGTTGCTCTGCAGATGGTGGGA TTCTCTAACCCTCCTGTGCTTATCAAGCACGGTAAAG GTGGTAAGAGGACCGTGCGTAGGCTTAACGAAGATG ATCCTGTTGCTAGAGGCATGCGGACTCAAGAAGAGG AAGAAGAACCTAGCGAAGCCGAGTCTGAGATTACC GTGATGAACCCTCTTTCCGTGCCTATCGTTAGCGCTT GGGAGAAAGGTATGGAAGCTGCAAGGGCTCTGATG GACAAGTACCATGTGGATAACGACCTGAAGGCCAAC TTCAAGCTGCTTCCAGATCAGGTTGAAGCTCTTGCTG CTGTGTGCAAGACCTGGCTTAATGAGGAACATAGGG GTCTGCAGCTGACCTTCACTAGCAACAAGACTTTCG TGACCATGATGGGCCGTTTCTTGCAGGCTTACCTTCA GTCTTTTGCCGAGGTGACCTACAAGCACCATGAGCC TACTGGTTGTGCTCTTTGGCTTCATAGGTGCGCTGAA ATTGAGGGTGAGCTTAAGTGCCTGCACGGCAGCATC ATGATCAACAAAGAACACGTGATCGAGATGGACGT GACCTCTGAAAATGGTCAGCGGGCTCTTAAAGAGCA GTCCAGCAAGGCTAAGATCGTGAAGAATAGGTGGG GCAGAAACGTGGTGCAGATCTCTAATACTGACGCCA GATGCTGCGTTCACGATGCTGCTTGTCCTGCTAATCA GTTCAGCGGTAAGAGCTGCGGCATGTTCTTTAGTGA GGGTGCTAAGGCTCAGGTGGCCTTCAAGCAGATCAA GGCTTTTATGCAGGCTCTGTACCCTAACGCTCAGACT GGTCATGGTCATCTGCTTATGCCTCTTAGGTGCGAGT GCAACTCTAAGCCTGGTCATGCTCCATTTCTTGGCAG GCAGCTTCCTAAGCTTACCCCTTTCGCTCTTAGCAAC GCTGAGGATCTTGATGCCGATCTGATCAGCGATAAG TCCGTGCTTGCTTCTGTGCATCACCCTGCTCTTATTGTGTTCCAGTGCTGCAACCCTGTGTACCGGAATTCTAG AGCACAAGGTGGTGGTCCTAACTGCGACTTCAAGAT CTCTGCTCCAGATCTGCTTAACGCCCTGGTGATGGTT AGATCTCTGTGGTCCGAGAACTTCACCGAGTTGCCT AGAATGGTTGTGCCCGAGTTCAAGTGGTCTACCAAG CACCAGTATCGGAACGTGTCACTTCCTGTGGCTCATT CTGATGCTAGGCAGAACCCTTTCGACTTCTAG WT ScFKBP46 Coding ATGTTTTGGGGACTTATTATGGAACCGAACAAACGG (SEQ ID NO: 20) TACACCCAAGTGGTGGAGAAACCGTTCCACATCTCA CAGGCAGCTATGGACATCAGCACCGGAGACAATGAT CCCTGCCAAGTTATGGTAGTAGTCGATGGCAAGAAC TTCCTAGTGTGCACATTACAGAAGGGCAAGATTATC CAGGTGCCCTTGGACTTGTATTTCAAATCTGGAGATT CAGTTTCATTCTTGACAAATGGTAAATGCAATGTTCA CTTGACTGGTTACCTTGATCCTGAGTTTGAGGAGGAT TTGGAGGATGAGGAAGAGGCTGAAGAAGAAGAGGA GGAGGAGGAGGCTCCACCTCTAGTGCCAGCTAAGAA TAAGAGGAAACTCGAGAATGCCAATGATGCCACAG CTAACAAAAAGGCCAAGCCTGACAAGAAAGCTGGC AAGAACAGTGCACCAGCAGCAGAAAGTGATTCAGA TGACGATGATGAAGACCAGCTTCAAAAGTTCCTTGA CGGAGAAGATATAGACACTGATGAAAATGATGAAT CATTCAAAATGAACACATCAGCTGAAGGAGATGACA GTGATGAAGAGGATGATGATGAAGACGAAGAGGAT GAAGAAGATGATGATGAGGACGATGAAGAAGAGGT AGAAGAAGCACCCAAGAAGAAGAAGAAACAGCCAG CCGCAGAGCAGGACTCAACACTGGACACAAGCAAG GAGTCTGTGGACATGTCCAAACTGTCCAAGTCACAG AAGAGAAGGCTCAAGAAGAAGCTCCAACAACAAGC TAAACAACAGCCTCAAGTCAATGGAGTTGATAAGCC TAAGAAAGAGGAACCCCAACAGAAGGCTGAAAAGAAGAAGCCTGAGGCCAAGAAAGAAGAGGCTCCAGTA GAGAAGAAAGAAAAGAAACAAATTGCTGGTGGTGT TTCTATTGAAGACCTCAAGGTCGGTTCTGGACCTGTT GCTAAGGCTGGCAAAGTTGTAATGGTTTACTATGAA GGTCGCCTTAAGCAAAACAACAAGATGTTTGACAAC TGTGTGAAAGGACCCGGCTTCAAGTTCCGCCTAGGA TCCAAGGAGGTCATCTCTGGCTGGGATGTAGGTATT GCTGGCATGAAGGTTGGAGGCAAGAGGAAGATCGT CTGCCCACCTGCGATGGCGTATGGAGCCAAAGGATC ACCTCCAGTCATCCCACCAAACTCAACTCTAGTATTT GAAGTTGAACTGAAGAATGTGAAATAACodon optimized FKBP46 ATGTTCTGGGGTCTTATCATGGAACCGAACAAGCGG Coding TACACTCAGGTGGTGGAAAAGCCGTTCCATATCTCT (SEQ ID NO: 21) CAGGCTGCCATGGATATTAGCACCGGCGATAATGAT CCTTGCCAGGTTATGGTTGTGGTGGACGGTAAGAAC TTCCTTGTGTGCACTCTGCAGAAGGGCAAGATTATTC AGGTGCCACTGGACCTGTACTTCAAGAGCGGTGATT CTGTGAGCTTCCTGACCAACGGTAAGTGCAACGTTC ACCTGACCGGATACCTTGATCCTGAGTTCGAAGAGG ATCTTGAGGACGAAGAAGAGGCCGAAGAAGAAGAG GAAGAGGAAGAAGCTCCTCCTCTGGTTCCTGCTAAG AACAAGCGTAAGCTTGAGAACGCTAACGACGCTACC GCTAACAAGAAGGCTAAGCCTGATAAGAAGGCCGG CAAGAATTCTGCTCCTGCTGCTGAGTCTGATAGCGA CGATGATGATGAGGACCAGCTGCAAAAGTTCCTGGA TGGCGAGGATATCGATACCGATGAGAACGACGAGA GCTTCAAGATGAACACCTCTGCTGAGGGCGACGATT CCGATGAAGAGGATGATGACGAAGATGAAGAGGAC GAAGAGGATGACGATGAGGACGATGAAGAAGAGGT TGAAGAGGCCCCTAAGAAGAAAAAGAAGCAGCCAG CTGCTGAGCAGGATTCTACCCTGGATACCAGCAAAGAAAGCGTGGACATGAGCAAGCTGAGCAAGTCTCAG AAGCGGCGGCTTAAGAAGAAGCTTCAACAACAGGC TAAGCAGCAGCCGCAGGTTAACGGTGTTGACAAGCC TAAGAAAGAGGAACCGCAGCAGAAGGCTGAGAAGA AGAAACCTGAGGCTAAGAAAGAAGAGGCTCCGGTC GAGAAGAAAGAGAAAAAGCAGATTGCTGGCGGCGT GAGCATCGAGGATCTTAAGGTTGGATCTGGTCCTGT GGCTAAGGCTGGTAAGGTTGTGATGGTTTACTACGA GGGCCGTCTGAAGCAGAACAACAAGATGTTCGACA ACTGCGTGAAAGGCCCTGGCTTCAAGTTTAGGCTGG GCTCTAAAGAGGTGATCAGCGGTTGGGATGTTGGTA TCGCTGGTATGAAGGTTGGCGGGAAGAGAAAGATTG TGTGCCCTCCTGCTATGGCTTACGGTGCTAAGGGTTC TCCTCCTGTGATTCCTCCAAACAGCACTCTTGTGTTC GAGGTCGAGCTGAAGAACGTGAAGTAGCodon optimized 55K Coding ATGGAACGGCGTAATCCTTCTGAGAGAGGTGTTCCT (SEQ ID NO: 22) GCTGGTTTCTCTGGTCATGCCTCTGTTGAATCTGGCT GCGAGACTCAAGAATCTCCTGCTACTGTTGTGTTCA GGCCACCTGGTGATAATACCGATGGTGGTGCAGCTG CTGCTGCCGGTGGTTCTCAAGCTGCCGCTGCTGGTGC TGAACCTATGGAACCTGAATCAAGACCTGGTCCGAG CGGTATGAATGTTGTTCAGGTTGCAGAGCTGTACCC TGAGCTGAGAAGGATTCTTACCATCACCGAAGATGG TCAGGGTCTGAAGGGTGTTAAGCGTGAAAGGGGAG CTTGCGAAGCTACTGAAGAGGCTAGGAACCTTGCCT TCTCACTTATGACTAGGCATCGGCCTGAGTGCATTAC CTTCCAGCAGATCAAGGACAACTGCGCTAACGAGCT TGATCTCCTGGCTCAGAAGTACAGCATTGAGCAGCT TACCACCTACTGGCTTCAGCCTGGTGATGATTTCGAA GAGGCAATCCGGGTGTACGCTAAGGTTGCACTTAGA CCTGACTGCAAGTACAAGATCAGCAAGCTGGTGAACATCCGTAACTGCTGCTACATCTCTGGTAACGGTGCC GAGGTTGAGATTGATACCGAGGATAGAGTTGCCTTC CGGTGCAGCATGATTAACATGTGGCCTGGTGTGCTT GGCATGGATGGTGTGGTGATTATGAACGTGAGGTTC ACCGGGCCTAACTTCTCTGGTACTGTGTTCCTTGCTA ACACCAACCTGATTCTGCACGGCGTGTCATTCTACG GCTTCAACAATACTTGCGTCGAGGCTTGGACTGATG TGAGAGTTAGAGGTTGCGCTTTCTACTGCTGCTGGA AAGGTGTTGTGTGCCGTCCTAAGTCTCGGGCCTCTAT TAAGAAGTGCCTTTTCGAGAGGTGCACCCTGGGTAT TCTTTCTGAGGGAAACTCTCGTGTGAGGCACAACGT TGCATCTGATTGCGGTTGCTTCATGCTGGTGAAGTCT GTGGCTGTGATCAAGCACAATATGGTGTGCGGTAAC TGCGAGGATAGGGCTTCTCAGATGCTTACCTGCTCT GATGGTAACTGCCACCTCCTCAAGACCATTCATGTG GCTTCTCACTCTAGGAAGGCTTGGCCTGTTTTCGAGC ACAACATTCTGACCAGGTGCAGCCTTCACCTTGGTA ATAGAAGGGGAGTGTTCCTTCCGTACCAGTGCAATC TTTCCCACACCAAGATTCTGCTTGAGCCCGAGAGCA TGTCTAAGGTGAACTTGAACGGCGTGTTCGACATGA CCATGAAGATTTGGAAGGTGCTGCGGTACGATGAGA CTAGGACTAGATGTAGACCTTGCGAGTGTGGTGGCA AGCACATTAGGAATCAGCCAGTGATGCTTGACGTGA CCGAGGAACTTAGGCCAGATCATCTTGTGCTTGCTT GCACTAGGGCTGAGTTCGGTTCTTCTGATGAGGATA CCGACTAGCodon optimized 22K-33K GCCCCTAAGAAGAAGTTGCAGCTTCCTCCTCCACCT Coding ACCGACGAAGAAGAGTATTGGGATTCTCAGGCTGAA (SEQ ID NO: 23) GAGGTGCTGGACGAAGAGGAAGAGGACATGATGGA AGATTGGGAGAGCCTGGATGAAGAGGCTTCTGAAGC CGAAGAGGTGTCAGATGAGACTCCTAGTCCTTCTGTGGCTTTCCCATCTCCTGCTCCTCAAAAGTCTGCTACC GGATCTTCTATGGCTACCACTTCAGCTCCTCAAGCTC CTCCTGCTTTGCCTGTTAGAAGGCCAAATAGAAGGT GGGATACCACCGGAACTAGAGCCGGTAAGTCTAAGC AACCTCCACCTCTTGCTCAAGAGCAACAACAGAGGC AAGGTTACAGGTCTTGGAGGGGTCATAAGAACGCTA TTGTGGCTTGCCTTCAGGATTGCGGTGGCAACATTTC TTTCGCTAGGCGGTTCCTTCTTTACCACCACGGTGTT GCTTTCCCGAGGAACATTCTTCACTACTACCGGCACC TGTACTCCCCATATTGCACTGGTGGTAGCGGCTCTAA TTCTTCTGGTCATACTGAGGCTAAGGCCACCGGATA GCAAGACCCTGACCAAGCCTAAGAAGTCTACAGCTG CTGCTGCCGCTGGTGGTGGCGCTTTAAGACTTGCTCC TAATGAGCCTGTGAGCACCAGAGAGCTTAGGAACAG GATTTTCCCTACCTTGTACGCCATCTTCCAGCAGTCT AGGGGTCAAGAGCAAGAGCTGAAGATCAAGAACCG TAGCCTTCGGTCTTTGACCAGGTCTTGCCTTTACCAC AAGAGCGAGGATCAGCTTAGAAGGACCCTTGAAGA TGCTGAGGCCCTGTTCTCTAAGTATTGCGCTCTTACC CTGAAGGACTAGCCCGGCodon optimized UL5 Coding ATGGCTGCTGCTGGTGGTGAAAGACAACTTGATGGT (SEQ ID NO: 24) CAAAAGCCTGGGCCTCCTCATCTTCAACAACCTGGT GATAGACCTGCTGTTCCTGGTAGAGCTGAGGCTTTC CTTAACTTCACCTCTATGCATGGCGTGCAGCCTATCC TTAAGAGGATCAGAGAACTGAGCCAACAGCAGCTG GATGGTGCTCAAGTTCCACATCTTCAGTGGTTCAGG GATGTCGCTGCTCTTGAATCTCCTGCTGGTTTGCCTC TTCGTGAGTTCCCTTTCGCTGTGTACCTTATTACCGG CAACGCTGGTTCTGGTAAGTCTACTTGCGTGCAGAC CATTAACGAGGTGTTGGATTGCGTTGTGACTGGCGC TACTAGAATCGCTGCTCAGAACATGTACGCTAAGCTGTCTGGTGCTTTCCTGAGCAGGCCAATCAACACCAT TTTCCACGAGTTCGGTTTCAGGGGTAATCACGTTCAA GCTCAGCTTGGGCAGTACCCTTACACCTTGACTTCTA ACCCTGCCAGCCTTGAGGATCTCCAGAGAAGGGATC TTACCTACTACTGGGAAGTGATCCTGGACCTTACCA AGAGAGCTTTGGCTGCATCAGGTGGTGAGGAACTTA GGAATGAGTTCAGGGCTCTTGCTGCTTTGGAGAGGA CTCTTGGTCTTGCTGAAGGTGCTCTTACTAGGCTTGC TCCTGCTACTCATGGTGCTTTGCCAGCTTTCACCAGG TCTAACGTGATCGTGATTGATGAGGCTGGTCTGCTTG GTAGGCATCTTCTTACTGCTGTTGTGTATTGCTGGTG GATGATCAACGCCCTGTACCACACTCCTCAGTATGC TGCTAGACTTAGGCCAGTTCTTGTGTGCGTTGGTTCT CCTACTCAGACCGCTTCTCTTGAGTCTACCTTCGAGC ACCAAAAGCTCAGGTGCTCTGTTCGGCAGTCTGAGA ATGTGCTTACCTACCTGATCTGCAACAGGACCCTTA GAGAGTACGCTCGGCTTTCTTACAGCTGGGCCATCTT CATCAACAACAAGCGGTGTGTTGAGCATGAGTTCGG CAACCTGATGAAGGTTTTGGAGTACGGTCTGCCGAT TACCGAGGAACACATGCAGTTCGTGGATCGGTTTGT TGTGCCCGAGAACTACATTACTAACCCGGCTAATCT TCCTGGCTGGACCAGGCTGTTTAGCAGCCACAAAGA GGTGTCAGCCTACATGGCTAAGCTGCACGCTTACTT GAAGGTTACAAGAGAGGGCGAGTTCGTCGTTTTCAC CCTTCCTGTTCTTACCTTCGTGAGCGTGAAAGAGTTC GACGAGTACAGAAGGCTTACTCACCAGCCTGGTTTG ACCATTGAGAAGTGGCTTACCGCTAACGCCTCTCGG ATTACCAACTACTCTCAGAGCCAAGATCAGGACGCT GGTCACATGAGATGTGAGGTTCACTCTAAGCAGCAG CTTGTGGTGGCTAGGAACGATGTGACTTACGTGCTG AACTCTCAGATCGCTGTGACTGCTAGGTTGCGGAAGTTGGTGTTTGGTTTCTCTGGAACCTTCCGGGCTTTCG AGGCTGTTCTTAGGGATGACTCTTTCGTTAAGACCCA GGGCGAGACTTCTGTCGAGTTCGCTTACAGATTCCT GTCCAGGCTGATCTTCTCCGGCCTGATCTCTTTCTAC AACTTCCTTCAGAGGCCAGGTCTGGATGCTACTCAG AGGACTTTGGCTTATGCTAGGATGGGTGAACTGACC GCTGAGATTTTGAGCCTGAGGCCAAAGTCTAGTGGT GTGCCTACTCAGGCTTCTGTGATGGCAGATGCTGGT GCTCCTGGTGAGAGGGCTTTTGATTTTAAGCAGCTC GGTCCTAGAGATGGCGGCCCTGATGATTTTCCTGAT GATGATCTGGACGTCATCTTCGCTGGTCTTGATGAGC AACAGCTGGACGTGTTCTACTGCCATTATACACCTG GTGAGCCAGAGACTACTGCTGCTGTTCATACTCAGT TCGCTCTGCTGAAGAGGGCATTCCTTGGCAGGTTCA GGATTCTGCAAGAGCTTTTCGGAGAGGCATTCGAGG TTGCACCGTTCTCTACTTACGTGGACAACGTGATCTT TCGGGGTTGCGAGATGCTTACCGGATCTCCTAGAGG TGGTCTTATGTCTGTGGCACTCCAGACCGATAACTAC ACCCTTATGGGTTACACCTACGCTCGGGTTTTCGCTT TCGCTGATGAGCTTAGAAGAAGGCACGCTACCGCTA ATGTGGCTGAGCTTCTTGAAGAGGCTCCTCTTCCTTA CGTGGTGCTTAGAGATCAGCACGGCTTCATGTCTGT CGTGAACACCAACATCTCCGAGTTCGTTGAGAGCAT CGACTCTACCGAACTGGCTATGGCTATCAACGCTGA CTACGGCATCAGCAGCAAGCTGGCTATGACCATTAC TAGGTCCCAGGGCCTGTCTTTGGATAAGGTGGCAAT TTGCTTCACCCCTGGGAACCTGAGGCTCAACTCTGCT TATGTTGCTATGAGCCGGACCACCAGCTCTGAGTTC CTTAGGATGAACTTGAACCCTCTGCGTGAGAGGCAT GAGAGGGATGATGTGATTTCTGAGCACATCCTGTCT GCTCTGAGGGACCCTAATGTGGTGATTGTGTACTAGCodon optimized UL52 ATGGGTCAAGAGGATGGTAATAGAGGTGAGCGTAG Coding AGCTGCTGGTACTCCTGTTGAAGTGACTGCTCTTTAC (SEQ ID NO: 25) GCTACCGATGGTTGCGTGATAACCTCCTCTATTGCTC TGCTGACCAACTCTTTGCTTGGTGCTGAGCCGGTCTA CATCTTCAGCTACGATGCTTACACCCACGATGGTAG AGCTGATGGACCTACTGAGCAGGATAGGTTCGAAGA GTCTAGGGCTCTTTACCAGGCTTCTGGTGGTCTGAAC GGCGATTCTTTCAGAGTGACCTTCTGCCTTCTTGGCA CTGAGGTTGGAGGTACTCATCAGGCTAGAGGTAGGA CTAGGCCAATGTTTGTGTGCAGGTTTGAGAGGGCTG ATGATGTGGCTGCACTTCAGGATGCTCTTGCTCATGG TACACCTCTTCAGCCTGATCACATTGCTGCTACCCTT GATGCTGAGGCTACTTTTGCTCTGCACGCCAACATG ATTCTTGCTCTGACCGTGGCTATCAACAACGCTTCTC CTAGAACTGGTAGGGATGCTGCTGCTGCACAATATG ATCAGGGTGCTAGTCTGCGGTCTTTGGTTGGTAGAA CTTCTCTTGGTCAGAGGGGTCTGACCACACTTTACGT TCACCATGAGGTGAGAGTGCTGGCTGCTTATAGAAG GGCTTACTACGGTTCTGCTCAGAGCCCTTTCTGGTTC CTGTCTAAGTTTGGCCCTGACGAGAAGTCTCTTGTGC TGACTACTAGGTACTACCTGCTTCAGGCTCAGAGAC TTGGTGGTGCTGGTGCTACTTATGACCTCCAGGCTAT TAAGGACATCTGCGCCACTTACGCTATTCCTCATGCT CCAAGGCCAGATACTGTGTCTGCTGCTTCTCTTACCA GCTTCGCTGCTATCACTAGGTTTTGCTGCACCTCTCA GTATGCTAGGGGCGCTGCTGCCGCTGGTTTTCCACTT TATGTTGAGAGAAGGATCGCTGCCGATGTGAGGGAA ACTTCTGCTCTTGAGAAGTTCATCACCCACGACAGG TCTTGCCTTAGGGTGTCAGATCGTGAGTTCATTACCT ACATCTACCTGGCTCACTTCGAGTGCTTTAGCCCTCC TAGACTTGCTACTCATCTTCGGGCTGTGACTACCCACGATCCTAATCCAGCTGCTTCTACAGAACAGCCTTCTC CACTTGGAAGGGAAGCTGTTGAGCAGTTCTTCTGCC ATGTTAGGGCTCAGCTTAACATCGGCGAGTACGTGA AGCACAATGTGACTCCAAGGGAAACCGTGCTGGATG GTGATACTGCTAAGGCTTACCTTAGGGCTAGAACCT ATGCTCCTGGTGCTCTTACTCCTGCTCCTGCTTATTG TGGTGCTGTGGATTCTGCCACCAAGATGATGGGAAG ATTGGCTGACGCTGAGAAGCTGCTTGTTCCTAGAGG TTGGCCTGCTTTTGCTCCAGCTTCTCCTGGTGAAGAT ACTGCTGGTGGAACTCCTCCTCCTCAAACTTGCGGTA TTGTGAAGAGGCTTCTGAGGCTTGCTGCAACTGAAC AACAAGGTCCTACTCCTCCAGCTATCGCAGCTCTTAT TAGGAACGCTGCTGTGCAGACTCCTCTGCCTGTTTAC AGGATTAGCATGGTGCCTACTGGTCAGGCTTTTGCT GCTTTGGCTTGGGATGATTGGGCTAGAATTACCAGG GATGCTAGGTTGGCTGAGGCTGTTGTTTCTGCTGAA GCTGCTGCTCATCCTGATCATGGTGCACTTGGTAGA AGGCTGACCGATAGGATTAGAGCACAGGGTCCTGTT ATGCCACCTGGTGGTTTGGATGCTGGTGGTCAGATG TACGTGAACCGGAACGAGATTTTCAACGGCGCTCTT GCCATCACCAACATCATCCTGGATCTGGACATTGCC CTGAAAGAGCCTGTTCCATTCAGAAGGCTTCACGAG GCTCTTGGACATTTCAGAAGAGGTGCTCTTGCAGCT GTGCAGCTTTTGTTTCCTGCTGCTAGAGTTGACCCTG ACGCTTACCCTTGCTACTTCTTCAAGTCTGCTTGCAG ACCTGGGCCTGCTTCTGTTGGTTCTGGTTCTGGACTT GGCAACGATGATGATGGCGATTGGTTCCCATGCTAC GATGACGCTGGTGATGAAGAGTGGGCTGAAGATCCA GGTGCTATGGATACTTCTCACGATCCTCCAGATGAT GAGGTGGCCTACTTCGATCTTTGCCATGAAGTTGGTC CTACCGCTGAGCCTAGAGAGACTGATTCTCCTGTTTGCTCCTGCACCGATAAGATCGGTCTGAGAGTGTGTAT GCCAGTGCCTGCTCCTTATGTGGTGCACGGTTCTCTT ACTATGAGGGGTGTTGCTAGGGTTATCCAGCAGGCT GTTTTGCTGGATAGGGACTTCGTTGAGGCTATCGGCT CTTACGTGAAGAACTTCCTGCTGATCGACACTGGTG TGTACGCTCACGGTCATTCTCTTAGGTTGCCTTACTT CGCTAAGATCGCTCCTGATGGTCCTGCTTGCGGTAG ACTTCTTCCTGTGTTCGTTATCCCTCCTGCCTGCAAG GATGTTCCTGCTTTCGTTGCTGCACACGCTGATCCTA GAAGGTTCCATTTTCATGCTCCTCCGACCTACCTTGC TTCCCCAAGAGAGATTAGGGTCCTGCATTCTCTTGGC GGCGATTACGTTTCATTCTTCGAGCGTAAGGCTTCCC GGAACGCTCTTGAGCATTTTGGGAGAAGAGAGACTC TGACCGAAGTCCTTGGTAGGTACAATGTGCAACCTG ATGCTGGCGGTACTGTTGAGGGTTTTGCTTCTGAGCT TCTCGGCAGAATTGTGGCCTGTATCGAGACTCATTTT CCTGAACACGCTGGCGAGTATCAGGCTGTGTCAGTT AGAAGGGCAGTGAGCAAGGATGACTGGGTTCTGCTT CAGCTTGTTCCAGTGAGAGGAACCCTTCAGCAGTCT CTTTCATGCCTGAGGTTTAAGCACGGTAGGGCTTCA AGAGCTACTGCTAGGACTTTCGTGGCTCTTTCTGTGG GTGCTAACAACAGGCTTTGCGTGTCACTTTGCCAGC AGTGCTTTGCTGCTAAGTGCGATTCTAACAGGCTGC ACACCCTTTTCACTATCGACGCAGGTACTCCTTGCTC TCCATCTGTTCCATGCTCTACCTCTCAGCCGTCATCT TAG WT E2A Coding ATGGCCAGTCGGGAAGAGGAGCAGCGCGAAACCAC (SEQ ID NO: 26) CCCCGAGCGCGGACGCGGTGCGGCGCGACGTCCCCC AACCATGGAGGACGTGTCGTCCCCGTCCCCGTCGCC GCCGCCTCCCCGGGCGCCCCCAAAAAAGCGGATGAG GCGGCGTATCGAGTCCGAGGACGAGGAAGACTCATCACAAGACGCGCTGGTGCCGCGCACACCCAGCCCGCG GCCATCGACCTCGGCGGCGGATTTGGCCATTGCGCC CAAGAAGAAAAAGAAGCGCCCTTCTCCCAAGCCCG AGCGCCCGCCATCACCAGAGGTAATCGTGGACAGCG AGGAAGAAAGAGAAGATGTGGCGCTACAAATGGTG GGTTTCAGCAACCCACCGGTGCTAATCAAGCATGGC AAAGGAGGTAAGCGCACAGTGCGGCGGCTGAATGA AGACGACCCAGTGGCGCGTGGTATGCGGACGCAAG AGGAAGAGGAAGAGCCCAGCGAAGCGGAAAGTGAA ATTACGGTGATGAACCCGCTGAGTGTGCCGATCGTG TCTGCGTGGGAGAAGGGCATGGAGGCTGCGCGCGC GCTGATGGACAAGTACCACGTGGATAACGATCTAAA GGCGAACTTCAAACTACTGCCTGACCAAGTGGAAGC TCTGGCGGCCGTATGCAAGACCTGGCTGAACGAGGA GCACCGCGGGTTGCAGCTGACCTTCACCAGCAACAA GACCTTTGTGACGATGATGGGGCGATTCCTGCAGGC GTACCTGCAGTCGTTTGCAGAGGTGACCTACAAGCA TCACGAGCCCACGGGCTGCGCGTTGTGGCTGCACCG CTGCGCTGAGATCGAAGGCGAGCTTAAGTGTCTACA CGGAAGCATTATGATAAATAAGGAGCACGTGATTGA AATGGATGTGACGAGCGAAAACGGGCAGCGCGCGC TGAAGGAGCAGTCTAGCAAGGCCAAGATCGTGAAG AACCGGTGGGGCCGAAATGTGGTGCAGATCTCCAAC ACCGACGCAAGGTGCTGCGTGCACGACGCGGCCTGT CCGGCCAATCAGTTTTCCGGCAAGTCTTGCGGCATG TTCTTCTCTGAAGGCGCAAAGGCTCAGGTGGCTTTTA AGCAGATCAAGGCTTTTATGCAGGCGCTGTATCCTA ACGCCCAGACCGGGCACGGTCACCTTTTGATGCCAC TACGGTGCGAGTGCAACTCAAAGCCTGGGCACGCGC CCTTTTTGGGAAGGCAGCTACCAAAGTTGACTCCGT TCGCCCTGAGCAACGCGGAGGACCTGGACGCGGATCTGATCTCCGACAAGAGCGTGCTGGCCAGCGTGCACC ACCCGGCGCTGATAGTGTTCCAGTGCTGCAACCCTG TGTATCGCAACTCGCGCGCGCAGGGCGGAGGCCCCA ACTGCGACTTCAAGATATCGGCGCCCGACCTGCTAA ACGCGTTGGTGATGGTGCGCAGCCTGTGGAGTGAAA ACTTCACCGAGCTGCCGCGGATGGTTGTGCCTGAGT TTAAGTGGAGCACTAAACACCAGTATCGCAACGTGT CCCTGCCAGTGGCGCATAGCGATGCGCGGCAGAACC CCTTTGATTTTTAACodon optimized E2A Coding ATGGCCAGCCGTGAAGAGGAACAGAGAGAAACTAC (SEQ ID NO: 27) TCCTGAGAGAGGTAGGGGAGCTGCTAGAAGGCCTCC TACTATGGAAGATGTGTCCTCTCCATCTCCTAGTCCT CCGCCTCCTAGGGCTCCTCCTAAGAAAAGAATGAGG CGTAGGATCGAGAGCGAGGACGAAGAGGATTCTTCT CAGGATGCTCTTGTGCCGAGAACACCTTCTCCTAGG CCTTCAACTTCTGCTGCTGATCTTGCTATCGCCCCAA AGAAGAAGAAAAAGCGGCCTTCTCCAAAGCCTGAG AGGCCTCCTTCACCTGAGGTTATCGTTGACAGCGAA GAGGAACGTGAGGATGTTGCTCTGCAGATGGTGGGA TTCTCTAACCCTCCTGTGCTTATCAAGCACGGTAAAG GTGGTAAGAGGACCGTGCGTAGGCTTAACGAAGATG ATCCTGTTGCTAGAGGCATGCGGACTCAAGAAGAGG AAGAAGAACCTAGCGAAGCCGAGTCTGAGATTACC GTGATGAACCCTCTTTCCGTGCCTATCGTTAGCGCTT GGGAGAAAGGTATGGAAGCTGCAAGGGCTCTGATG GACAAGTACCATGTGGATAACGACCTGAAGGCCAAC TTCAAGCTGCTTCCAGATCAGGTTGAAGCTCTTGCTG CTGTGTGCAAGACCTGGCTTAATGAGGAACATAGGG GTCTGCAGCTGACCTTCACTAGCAACAAGACTTTCG TGACCATGATGGGCCGTTTCTTGCAGGCTTACCTTCA GTCTTTTGCCGAGGTGACCTACAAGCACCATGAGCCTACTGGTTGTGCTCTTTGGCTTCATAGGTGCGCTGAA ATTGAGGGTGAGCTTAAGTGCCTGCACGGCAGCATC ATGATCAACAAAGAACACGTGATCGAGATGGACGT GACCTCTGAAAATGGTCAGCGGGCTCTTAAAGAGCA GTCCAGCAAGGCTAAGATCGTGAAGAATAGGTGGG GCAGAAACGTGGTGCAGATCTCTAATACTGACGCCA GATGCTGCGTTCACGATGCTGCTTGTCCTGCTAATCA GTTCAGCGGTAAGAGCTGCGGCATGTTCTTTAGTGA GGGTGCTAAGGCTCAGGTGGCCTTCAAGCAGATCAA GGCTTTTATGCAGGCTCTGTACCCTAACGCTCAGACT GGTCATGGTCATCTGCTTATGCCTCTTAGGTGCGAGT GCAACTCTAAGCCTGGTCATGCTCCATTTCTTGGCAG GCAGCTTCCTAAGCTTACCCCTTTCGCTCTTAGCAAC GCTGAGGATCTTGATGCCGATCTGATCAGCGATAAG TCCGTGCTTGCTTCTGTGCATCACCCTGCTCTTATTG TGTTCCAGTGCTGCAACCCTGTGTACCGGAATTCTAG AGCACAAGGTGGTGGTCCTAACTGCGACTTCAAGAT CTCTGCTCCAGATCTGCTTAACGCCCTGGTGATGGTT AGATCTCTGTGGTCCGAGAACTTCACCGAGTTGCCT AGAATGGTTGTGCCCGAGTTCAAGTGGTCTACCAAG CACCAGTATCGGAACGTGTCACTTCCTGTGGCTCATT CTGATGCTAGGCAGAACCCTTTCGACTTCTAGCmYLCV promoter TGGCAGACATACTGTCCCACAAATGAAGATGGAATC (SEQ ID NO: 28) TGTAAAAGAAAACGCGTGAAATAATGCGTCTGACAA AGGTTAGGTCGGCTGCCTTTAATCAATACCAAAGTG GTCCCTACCACGATGGAAAAACTGTGCAGTCGGTTT GGCTTTTTCTGACGAACAAATAAGATTCGTGGCCGA CAGGTGGGGGTCCACCATGTGAAGGCATCTTCAGAC TCCAATAATGGAGCAATGACGTAAGGGCTTACGAAA TAAGTAAGGGTAGTTTGGGAAATGTCCACTCACCCG TCAGTCTATAAATACTTAGCCCCTCCCTCATTGTTAAGGGAGCAAAATCTCAGAGAGATAGTCCTAGAGAGA GAAAGAGAGCAAGTAGCCTAGAAGTAGTCAAGGCG GCGAAGTATTCAGGCAGGTGGCCAGGAAGAAGAAA AGCCAAGACGACGAAAACAGGTAAGAGCTAtUBQlO promoter CGACGAGTCAGTAATAAACGGCGTCAAAGTGGTTGC (SEQ ID NO: 29) AGCCGGCACACACGAGTCGTGTTTATCAACTCAAAG CACAAATACTTTTCCTCAACCTAAAAATAAGGCAAT TAGCCAAAAACAACTTTGCGTGTAAACAACGCTCAA TACACGTGTCATTTTATTATTAGCTATTGCTTCACCG CCTTAGCTTTCTCGTGACCTAGTCGTCCTCGTCTTTTC TTCTTCTTCTTCTATAAAACAATACCCAAAGAGCTCT TCTTCTTCACAATTCAGATTTCAATTTCTCAAAATCT TAAAAACTTTCTCTCAATTCTCTCTACCGTGATCAAG GTAAATTTCTGTGTTCCTTATTCTCTCAAAATCTTCG ATTTTGTTTTCGTTCGATCCCAATTTCGTATATGTTCT TTGGTTTAGATTCTGTTAATCTTAGATCGAAGACGAT TTTCTGGGTTTGATCGTTAGATATCATCTTAATTCTC GATTAGGGTTTCATAGATATCATCCGATTTGTTCAAA TAATTTGAGTTTTGTCGAATAATTACTCTTCGATTTG TGATTTCTATCTAGATCTGGTGTTAGTTTCTAGTTTG TGCGATCGAATTTGTCGATTAATCTGAGTTTTTCTGA TTAACAG NOS promoter GGGTTTCTGGAGTTTAATGAGCTAAGCACATACGTC (SEQ ID NO: 30) AGAAACCATTATTGCGCGTTCAAAAGTCGCCTAAGG TCACTATCAGCTAGCAAATATTTCTTGTCAAAAATGC TCCACTGACGTTCCATAAATTCCCCTCGGTATCCAAT TAGAGTCTCATATTCACTCTCAATCCAAATAATCTGC AAtACT2 promoter TCGACAAAATTTAGAACGAACTTAATTATGATCTCA (SEQ ID NO: 31) AATACATTGATACATATCTCATCTAGATCTAGGTTATCATTATGTAAGAAAGTTTTGACGAATATGGCACGACAAAATGGCTAGACTCGATGTAATTGGTATCTCAACT CAACATTATACTTATACCAAACATTAGTTAGACAAA ATTTAAACAACTATTTTTTATGTATGCAAGAGTCAGC ATATGTATAATTGATTCAGAATCGTTTTGACGAGTTC GGATGTAGTAGTAGCCATTATTTAATGTACATACTA ATCGTGAATAGTGAATATGATGAAACATTGTATCTT ATTGTATAAATATCCATAAACACATCATGAAAGACA CTTTCTTTCACGGTCTGAATTAATTATGATACAATTC TAATAGAAAACGAATTAAATTACGTTGAATTGTATG AAATCTAATTGAACAAGCCAACCACGACGACGACTA ACGTTGCCTGGATTGACTCGGTTTAAGTTAACCACTA AAAAAACGGAGCTGTCATGTAACACGCGGATCGAG CAGGTCACAGTCATGAAGCCATCAAAGCAAAAGAA CTAATCCAAGGGCTGAGATGATTAATTAGTTTAAAA ATTAGTTAACACGAGGGAAAAGGCTGTCTGACAGCC AGGTCACGTTATCTTTACCTGTGGTCGAAATGATTCG TGTCTGTCGATTTTAATTATTTTTTTGAAAGGCCGAA AATAAAGTTGTAAGAGATAAACCCGCCTATATAAAT TCATATATTTTCCTCTCCGCTTTGAAAtRbcS-2B Promoter GCTTAAGTGGGCCGTAAGTGCAATTGCGTTGTGCTC (SEQ ID NO: 32) CAAAAGGAACGGTGCCGTGGGTTCCTCTTGTTCATC AGAAATATATTAATTAGCCGTAAAACCTGAAAATTC ACAAGCATTTGGATTGTTTTCTAATTTAATATCCATT ATGTGACTAAAAGTTCTAGTGATCGTACATACTACA TAGAAAATAATAACACAAAATACTAGTTTACATTTC CCAATTAAAAACCATTTTGAATGAACTCTGTCTGATT TAATTATACTTTTAAAATGTGGGATGAATTCAAAGA TTATACTTATATTCTTATTATTTAAGATTATCAAGTG GAAAAATAAAAATATGAATGTGTTAATATAAGGTAA TAGAAATTTAATCATTTTTTTAATCTATATGTAAAAA GTATTTAACCGATATCTACAATTTGACGCCTCCCAATTGAAAGGAGCCAAAAGCAACCGATCAAGTGCAGAC CAGTAGCCATACACATTCACTCCTACCCTTACATGA GAAAGATAAGATTATGGAGTTTTCTGCCACGTGATC TTATCCTAGTGGTCCAAATCGATAAGGGTGTCAACA CCTTTCCTTAATCCTGTGGCAATTAACGACGTTATCA TGAATTATGGCCCCTTTGATCATTAGGGGCTTAAGTG GGCCGTAAGTGCAATTGCGTTGTGCTCCAAAAGGAA CGGTGCCGTGGGTTCCTCTTGTTCATCAGAAATATAT TAATTAGCCGTAAAACCTGAAAATTCACAAGCATTT GGATTGTTTTCTAATTTAATATCCATTATGTGACTAA AAGTTCTAGTGATCGTACATACTACATAGAAAATAA TAACACAAAATACTAGTTTACATTTCCCAATTAAAA ACCATTTTGAATGAACTCTGTCTGATTTAATTATACT TTTAAAATGTGGGATGAATTCAAAGATTATACTTAT ATTCTTATTATTTAAGATTATCAAGTGGAAAAATAA AAATATGAATGTGTTAATATAAGGTAATAGAAATTT AATCATTTTTTTAATCTATATGTAAAAAGTATTTAAC CGATATCTACAATTTGACGCCTCCCAATTGAAAGGA GCCAAAAGCAACCGATCAAGTGCAGACCAGTAGCC ATACACATTCACTCCTACCCTTACATGAGAAAGATA AGATTATGGAGTTTTCTGCCACGTGATCTTATCCTAG TGGTCCAAATCGATAAGGGTGTCAACACCTTTCCTT AATCCTGTGGCAATTAACGACGTTATCATGAATTAT GGCCCCTTTGATCATTAGGGCTAGTTGCCTCTAGCGG TTCCCACTATATAAAGATGACAAAACCAACAGAAtUBQll promoter TCTAGTGTTCAACATGACAAACAAAACCCATCTCTTT (SEQ ID NO: 33) CAGTATATGTCTCTCAGTTGTGCTTAATTCAAATTTC AACTCAGAGAACTTCTTGGCATACTTATCCAGATTAT CTAATGATCTCATCTAATGGTAATTCAACTTTCAGTA TATGTCTCGCAGCAAACTATCTTTACATCAAATTTTT AACAACTCAATGCACAAAATACTTTTCCTCAACCTAAAAATAAGGCAATTAGCCAAAAACAACTTTGCGTGT GAACAACGCGTACACGTCCCTACACATACGTGTCAA TTTATAATTGGCTATTGCTTCCACGCCTTAGCTTTCT CGTGACCGACCGAGTCGTCCTCGTCTTTTTTGCTTCT ATAAATCAAATACCCAAAGAGCTCTTCTTCTTCACA ATTCAGATTCCAATTTTCTCAAACTCTAAAATCAATC TCTCAAATCTCTCAACCGTGATCAAGGTAGATTTCTG AGTTCTTATTGTATTTCTTCGATTTGTTTCGTTCGATC GCAATTTAGGCTCTGTTCTTTGATTTTGATCTCGTTA ATCTCTGATCGGAGGCAAATTACATAGTTTCATCGTT AGATCTCTTCTTATTTCTCGATTAGGGTTCGTATTTTT CGCAGATCTGTTTATTTTCTTGTTGTTTCCTTGTATTT GATCCGATTTGTTGAAAGAATTTGTGTGTTCTCGATT ATTTACGCTTTGATCTGTGATTTTTATCTAGATTTGG TGTTAGTTTCTTGTTTGTGCGATCGAATTTGTCGATT AATCTCGGTTTTTCTGATTAACAGATGCAGATCTCTG GAGGTAGTGGAGGCAGTGGAAtCAB2 promoter GTGTTAACAGCTTTTATAGTTCAAAGTTTAGAATGTG (SEQ ID NO: 34) CTCTAAAGCATATGTGTGAGCCTGTGAGGTCTAGTG ATTGTAAAAAAGAAAAATTGTGCTTCGTGGAAAGTG ATGCAATAAACAACACTTCTAGGGCTGAGTAAAACC AACTAGACATGTAATGATAGCTTAAACCGTTTTCTAT AGGAGTGTGATTGAGGAGTAATTTGTTGATGAATTC GGAAAAAGCGAATAAATAAGTTTGTTCAAAAGGTTG TTGAAGTTTACAATAAAGATAACTTGAATCATGATA AGAAAAAAAGTAGCTATATGTTCTCTAAAGTCTAAA CCCATGATGATGAACATGCCATATGAATTAATATAG TTCTTTCATGTTCTTAGAAATGGTCGATAAGTTAAAA CAGTGTTTCATTAATCGTTGTGTTTCTTCGATAAAGA GTAAAACGTCAAAGTTTTAAGGTGATATCACATAAT TCATGAGATTATTTTGGTTATTGGATAAAGTGACGATGAAATCGATTCATAATTGAAATTAAACTGGTAGTGA TGATGAACTAATTACCATTGAAAATATTGATATTTAT GTGTGGGTAAATGCTTTTTATAATGTTACTTTATATT AATGTTTCGATCATCAGAATCTATATTTTCAAAATGT TATACTTTAAGTTTTAGTTATTGGGTTGTAGCAAAAA TCATTCTTGTCACGAGGGTGTAAGTAAGTGTAACCG TTGAAGTATTCAGTGGCTCATAACTTGTGGTCACAA AACGCTTGGCTGCAATGAAAAAATCAAAACAAATGC TGGTGGACTAGAGATTGCCACGTAAGACTACTAAAC GATAAAACAAAAATCTTAAAATCCAATGAATGAACA GATAAAGATTACTTCAGATATAACAAACGTTACAAT ATCCCTATATAATCCAACACTATCGAACCAGTTTTAA TCACTCTCACTCACAAGTTAGTCATAAAAAAAAAAA AAACACAAAAAAGTTTCACsVMV promoter CCAGAAGGTAATTATCCAAGATGTAGCATCAAGAAT (SEQ ID NO: 35) CCAATGTTTACGGGAAAAACTATGGAAGTATTATGT AAGCTCAGCAAGAAGCAGATCAATATGCGGCACAT ATGCAACCTATGTTCAAAAATGAAGAATGTACAGAT ACAAGATCCTATACTGCCAGAATACGAAGAAGAATA CGTAGAAATTGAAAAAGAAGAACCAGGCGAAGAAA AGAATCTTGATGACGTAAGCACTGACGACAACAATG AAAAGAAGAAGATAAGGTCGGTGATTGTGAAAGAG ACATAGAGGACACATGTAAGGTGGAAAATGTAAGG GCGGAAAGTAACCTTATCACAAAGGAATCTTATCCC CCACTACTTATCCTTTTATATTTTTCCGTGTCATTTTT GCCCTTGAGTTTTCCTATATAAGGAACCAAGTTCGG CATTTGTGAAAACAAGAAAAAATTTGGTGTAAGCTA TTTTCTTTGAAGTACTGAGGATACAACTTCAGAGAA ATTTGTAAGTTTGT LHBIB 1 promoter ATATGACTGGTAAGTTTTTCTTGCCAATACGAATTAG (SEQ ID NO: 36) AAAACATGTCTTTGAAGATGAACTGTATTTTTTTTTTTTACTTTGTTGTCATTTTAATGTACTTTCTTATCAGGA TTAAATCTTCTGTAATTTAGAGTAGTTTTTTTAACAA GATAATTAACAAACTTAGAGTAATGAAAATTGAGAT GTTCAGTTTTCACTCATATTTCACATTTTGGTGAAAG AGTGGGTAGTATGCAACGTTCTAAGTATGTTTGGAC TTTGTATCATGTTGTTTTGATTCTTTGACGACATGTCT ATTTGGGAAACACCAATGACGTGTACCTTGAGACTG ATACGATTCAAAGGGATAGAAACACGTCAGATTTAC AAGTGGCACCTCTTCAATGGACAATGGGTATTCCAA TATGCTAAGATGCTACGAGATATCTAATTTATCTAAC ACAACTCAATTCCAAACCAAAAATCTGATGCCAGCT CGACAAGACAAAAAATCTAAGCTCAAAAATGTCAA CAACCAATAGAAATCAAGGCATTGACGATATCACGA GATAAGCAAATTAAATCTTCAAGTTTTGCAATTCAT ATGTACGTTATAAATACCCAAAAACCTCACCGTAAC CTAGCTATCC LHBIB1 promoter TTGTTGCCGAAAACATTCAACAAAATCAATCAAAGG (SEQ ID NO: 37) TATCAGTTAATATCATTGTCGACGGTTTTATATTATT AACTTATGATCGTAAGAACTTCGTATCACTTTTTGTT TCATCTAACTGCATTGTTTTACATAACATTGATATAT ATTTGTTTGGTAAGTGTTTCTAGTTTCACTTAAAAAC TTTGTAGTTTGGCGTTCGAAACAAACTTGATAAGAA AAAAAAGAAAATATTATTGAGAGCATGAAGTGGATT GGAATTAAAGAAAACAAGGAAAAAGAAAAAAATAG ATTGGAATAATTTCAAATATTTCTTTCCAATAATTCA AGCATTTATCTTTGAAAATTTCCCCAAAGTTTCTTTG TGTACAAATGACAAGTGTTTTCGTTGCAGCTAAAGA ATCTAGCAAAAGCTTATGGACTAGAGAGTGACACAT AGGACAAGATAACGACAATCCCAAAATCTCATAAGC CAATCACTAAACAGATACAGATACTTCACAGATAACAAACCTTACTCTTAACATTGCTATAAAGTGGACGTA TACCCCAACCATTTTCAAM24-MMV promoter GAATTCGTCAACTTCGTCCACAGACATCAACATCTT (SEQ ID NO: 38) ATCGTCCTTTGAAGATAAGATAATAATGTTGAAGAT AAGAGTGGGAGCCCCCACTAAAACATTGCTTTGTCA AAAGCTAAAAAAGATGATGCCCGACAGCCACTTGTG TGAAGCATGAGAAGCCGGTCCCTCCACTAAGAAAAT TAGTGAAGCATCTTCCAGTGGTCCCTCCACTCACAG CTCAATCAGTGAGCAACAGGACGAAGGAAATGACG TAAGCCATGACGTCTAATCCCAACTTCGTCCACAGA CATCAACATCTTATCGTCCTTTGAAGATAAGATAAT AATGTTGAAGATAAGAGTG MAS promoter ATTTTTCAAATCAGTGCGCAAGACGTGACGTAAGTA (SEQ ID NO: 39) TCCGAGTCAGTTTTTATTTTTCTACTAATTTGGTCGTT TATTTCGGCGTGTAGGACATGGCAACCGGGCCTGAA TTTCGCGGGTATTCTGTTTCTATTCCAACTTTTTCTTG ATCCGCAGCCATTAACGACTTTTGAATAGATACGCT GACACGCCAAGCCTCGCTAGTCAAAAGTGTACCAAA CAACGCTTTACAGCAAGAACGGAATGCGCGTGACGC TCGCGGTGACGCCATTTCGCCTTTTCAGAAATGGAT AAATAGCCTTGCTTCCTATTATATCTTCCCAAATTAC CAATACATTACACTAGCATCTGAATTTCATAACCAA TCTCGATACACCAAATCGMinsynl08 Promoter TATATACAAATCAGTCACTACTGCTTTCAATGAATA (SEQ ID NO: 40) GCAAAACCTTATATAGTTTGTAGAGGTCTAGACGTC ATGGCTTACGTCATAAGCTGATAGCCTACATGTGAC GCAATAATGGTTGGTGCAGACAACCTTTGGGACCAC TGTCGGCAGAGAGAATCAGCATCGGTCCTCCTTCCC GCGTCATCGGCGGGGGTCATAAAAGGCAGGCAAGA TCGCTGATAGTGATGGTCGTGACCTACATCCACTTGC TCCTCACTAAAACGACACGCMiniSynl 10 promoter GCGTGTCGTTTTAGTGAGGGTGGGAGCCACCACACA (SEQ ID NO: 41) TGTAGGCTATCAGCTTAGCAATCGAAAGGACAGTAT GTGTACAGGGCTCACTAGCAAGTGGATAAACTGGTA CTTGTGTATGAAGATAAGATAATAATGTTGAAGATA AGATAGCAAGACCTCTACAACTGACGTAAGGGATGA CGCACACTGCTAGGAGGACATGACGTAAGCCATGAC GTCTACCGATGATGATCCTATATAAGGTTTTGCTATT CATTGAAAGCAGTAGTGACTGATTTGTATATAMinsynl556 promoter GCGTGTCGTTTTAGTGAGGGTGGGAGCCACCAGGTA (SEQ ID NO: 42) CTAACCATTATTGCGAAGACAGCAAGTGGATCACTA TTGCGATAAAGGAAAGGAATCCTTACCGCTATGGGT AAGATTACTATGCCCAATTAGGTTGTCTGCACCTATA TAAGGTTTTGCTATTCATTGAAAGCAGTAGTGACTG ATTTGTATATA35 S promoter GAATTCGAGCTCGGTACCCCCCTACTCCAAAAATGT (SEQ ID NO: 43) CAAAGATACAGTCTCAGAAGACCAAAGGGCTATTGA GACTTTTCAACAAAGGGTAATTTCGGGAAACCTCCT CGGATTCCATTGCCCAGCTATCTGTCACTTCATCGAA AGGACAGTAGAAAAGGAAGGTGGCTCCTACAAATG CCATCATTGCGATAAAGGAAAGGCTATCATTCAAGA TGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCC ACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTC CAACCACGTCTTCAAAGCAAGTGGATTGATGTGACA TCTCCACTGACGTAAGGGATGACGCACAATCCCACT ATCCTTCGCAAGACCCTTCCTCTATATAAGGAAGTTC ATTT2X35 S promoter AAGCTTGCATGCCTGCAGGTCAACATGGTGGAGCAC (SEQ ID NO: 44) GACACACTTGTCTACTCCAAAAATATCAAAGATACA GTCTCAGAAGACCAAAGGGCAATTGAGACTTTTCAA CAAAGGGTAATATCCGGAAACCTCCTCGGATTCCAT TGCCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCG ATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCG ACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGA GCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTT CAAAGCAAGTGGATTGATGTGATAACATGGTGGAGC ACGACACACTTGTCTACTCCAAAAATATCAAAGATA CAGTCTCAGAAGACCAAAGGGCAATTGAGACTTTTC AACAAAGGGTGATATCCGGAAACCTCCTCGGATTCC ATTGCCCAGCTATCTGTCACTTTATTGTGAAGATAGT GGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTG CGATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGC CGACAGTGGTCCCAAAGATGGACCCCCACCCACGAG GAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTC TTCAAAGCAAGTGGATTGATGTGATATCTCCACTGA CGTAAGGGATGACGCACAATCCCACTATCCTTCGCA AGACCCTTCCTCTATATAAGGAAGTTCATTTCATTTG GAGAGGACCTCGACCTCAACACAACATATACAAAAC AAACGAATCTCAAGCAATCAAGCATTCTACTTCTAT TGCAGCAATTTAAATCATTTCTTTTAAAGCAAAAGC AATTTTCTGAAAATTTTCACCATTTACGAACGATAStUBi promoter GAGGATGACAAGATTTTGGTCATCAATTACATATAC (SEQ ID NO: 45) CCAAATTGAATAGTAAGCAACTTAATGTTTTTCATA ATGATAATGACAGACACAAAAAAAACCCATTTATTA TTCACATTGATTGATTTTTATATGCAATATAGTAATA ATAATAATATTTCTTATAAAGCAAGAGGTCAATTTTT TTTTATTATACCAACGTCACTAAATTATATTTGATAA TGTAAAACAATTCAATTTTACTTAAATATCATGAAAT AAACTATTTTTATAACCAAATTACTAAATTTTTCCAA TAAAAAAAAGTCATTAAGAACACATAAAATAAATTT GAGTAAAAAGAGTGAAGTCGACTGACTTTTTTTTTTT TTATCATAAGAAAATAAATTATTAACTTTAACCTAATAAAACACTAATATAATTTCATGGAATCTAATACTTA CCTCTTAGAAATAAGAAAAAGTGTTTCTAATAGACC CTCAATTTACATTAAATATTTTCAATCAAATTTAAAT AACAAATATCAATATGAGGTCAATAACAATATCAAA ATAATATGAAAAAAGAGCAATACATAATATAAGAA AGAAGATTTAAGTGCGATTATCAAGGTAGTATTATA TCCTAATTTGCTAATATTTAAACTCTTATATTTAAGG TCATGTTCATGATAAACTTGAAATGCGCTATATTAG AGCATATATTAAAATAAAAAAATACCTAAAATAAAA TTAAGTTATTTTTAGTATATATTTTTTTACATGACCTA CATTTTTCTGGGTTTTTCTAAAGGAGCGTGTAAGTGT CGACCTCATTCTCCTAATTTTCCCCACCACATAAAAA TTAAAAAGGAAAGGTAGCTTTTGCGTGTTGTTTTGGT ACACTACACCTCATTATTACACGTGTCCTCATATAAT TGGTTAACCCTATGAGGCGGTTTCGTCTAGAGTCGG CCA CPMV-5’ UTR TATTAAAATCTTAATAGGTTTTGATAAAAGCGAACG (SEQ ID NO: 46) TGGGGAAACCCGAACCAAACCTTCTTCTAAACTCTC TCTCATCTCTCTTAAAGCAAACTTCTCTCTTGTCTTTC TTGCGTGAGCGATCTTCAACGTTGTCAGATCGTGCTT CGGCACCAGTACAACGTTTTCTTTCACTGAAGCGAA ATCAAAGATCTCTTTGTGGACACGTAGTGCGGCGCC ATTAAATAACGTGTACTTGTCCTATTCTTGTCGGTGT GGTCTTGGGAAAAGAAAGCTTGCTGGAGGCTGCTGT TCAGCCCCATACATTACTTGTTACGATTCTGCTGACT TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAG GTATTGTTGCCTGTACTTCTTTCTTCTTCTTCTTGCTG ATTGGTTCTATAAGAAATCTAGTATTTTCTTTGAAAC AGAGTTTTCCCGTGGTTTTCGAACTTGGAGAAAGAT TGTTAAGCTTCTGTATATTCTGCCCAAATTCGCGCPMV-3’UTR TTAACTCTGGTTTCATTAAATTTTCTTTAGTTTGAATT (SEQ ID NO: 47) TACTGTTATTCGGTGTGCATTTCTATGTTTGGTGAGC GGTTTTCTGTGCTCAGAGTGTGTTTATTTTATGTAAT TTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTCGTCC CTTCAGCAAGGACACAAAAAGATTTTAATTTTATT AMV-5’UTR TTTTTATTTTTAATTTTCTTTCAAATACTTCCATCA (SEQ ID NO: 48)TMV-omega\enhancer GTATTTTTACAACAATTACCAACAACAACAAACAAC (SEQ ID NO: 49) AAACAACATTACAATTACTATTTACAATTACA NbPsaK2-3-5’UTR ATAACAATTTAAACAAACAAAATCAACAAATATAGA (SEQ ID NO: 50) AAATAACGCATTTCCAATTCTTTGAAATTTCTGCAAC A TEV-5’UTR GAATTAATTCTCAACACAACATATACAAAACAAACG (SEQ ID NO: 51) AATCTCAAGCAATCAAGCATTCTACTTCTATTGCAGC AATTTAAATCATTTCTTTTAAAGCAAAAGCAATTTTC TGAAAATTTTCACCATTTACGAACGATAGA1MV-5’UTR GGATCCTCGAGCGGATCTTTTTATTTTTAATTTTCTTT (SEQ ID NO: 52) CAAATACTTCCANOS Terminator GATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGA (SEQ ID NO: 53) TTGAATCCTGTTGCCGGTCTTGCGATGATTATCATAT AATTTCTGTTGAATTACGTTAAGCATGTAATAATTAA CATGTAATGCATGACGTTATTTATGAGATGGGTTTTT ATGATTAGAGTCCCGCAATTATACATTTAATACGCG ATAGAAAACAAAATATAGCGCGCAAACTAGGATAA ATTATCGCGCGCGGTGTCATCTATGTTACTAGATC RBCSE9 Terminator GAGCTTTCGTTCGTATCATCGGTTTCGACAACGTTCG (SEQ ID NO: 54) TCAAGTTCAATGCATCAGTTTCATTGCGCACACACC AGAATCCTACTGAGTTCGAGTATTATGGCATTGGGA AACATGTTTTTCTTGTACCATTTGTTGTGCTTGTAATT TACTGTGTTTTTTATTCGGTTTTCGCTATCGAACTGT GAAATGGAAATGGATGGAGAAGAGTTAATGAATGATATGGTCCTTTTGTTCATTCTCAAATTAATATTATTTG TTTTTTCTCTTATTTGTTGTGTGTTGAATTTGAAAATA TAAGAGATATGCAAACATTTTGTTTTGAGTAAAAAT GTGTCAAATCGTGGCCTCTAATGACCGAAGTTAATA TGAGGAGTAAAACACTTGTAGTTGTACCATTATGCT TATTCACTAGGCAACAAATATATTTTCAGACCTAGA AAAGCTGCAAATGTTACTGAATACAAGTATGTCCTC TTGTGTTTTAGACATTTATGAACTTTCCTTTATGTAA TTTTCCAGAATCCTTGTCAGATTCTAATCATTGCTTT ATAATTATAGTTATACTCATGGATTTGTAGTTGAGTA TGAAAATATTTTTTAATGCATTTTATGACTTGCCAAT TGATTGACAACATGCATCA HSP18.2 Terminator ATATGAAGATGAAGATGAAATATTTGGTGTGTCAAA (SEQ ID NO: 55) TAAATAGCTTGTGTGCTTAAGTTTGTGTTTTTTTCTTG GCTTGTTGTGTTATGAATTTGTGGCTTTTTCTAATATT AAATGAATGTAAGATCTCATTATAATGAATAAACAA ATGTTTCTATAATCCATTGTGAATGTTTTGTTGGATC TCTTCTGCAGCATATAACTACTGTATGTGCTATGGTA TGGACTATGGAATATGATTAAAGATAAG35 S Terminator CTCGAATTCGCTGAAATCACCAGTCTCTCTCTACAAA (SEQ ID NO: 56) TCTATCTCTCTCTATTTTCTCCATAAATAATGTGTGA GTAGTTTCCCGATAAGGGAAATTAGGGTTCTTATAG GGTTTCGCTCATGTGTTGAGCATATAAGAAACCCTT AGTATGTATTTGTATTTGTAAAATACTTCTATCAATA AAATTTCTAATTCCTAAAACCAAAATCCAGTACTAA AATCCAGATCTCCTAAAGTCCCTATAGATCTTTGTCG TGAATATAAACCAGACACGAGACGACTAAACCTGG AGCCCAGACGCCGTTCGAAGCTAGAAGTACCGCTTA GGCAGGAGGCCGTTAGGGAAAAGATGCTAAGGCAG GGTTGGTTACGTTGACTCCCCCGTAGGTTTGGTTTAA ATATGATGAAGTGGACGGAAGGAAGGAGGAAGACAAGGAAGGATAAGGTTGCAGGCCCTGTGCAAGGTAA GAAGATGGAAATTTGATAGAGGTACGCTACTATACT TATACTATACGCTAAGGGAATGCTTGTATTTATACCC TATACCCCCTAATAACCCCTTATCAATTTAAGAAATA ATCCGCATAAGCCCCCGCTTAAAAATTGGTATCAGA GCCATGAATAGGTCTATGACCAAAACTCAAGAGGAT AAAACCTCACCAAAATACGAAAGAGTTCTTAACTCT AAAGATAAAAGAT NDUGA8t Terminator GAATCACAAGTTCTTGTCATGTTTTGATTTGTATCTC (SEQ ID NO: 57) ATAATAAAGCAAAATGTTCATTTTTGAATGAGCTTT ACTCTCTCCATCTCTTGTTTGTTGTCATCCCATTTATT TCCTCTCAGATGCTTTCGTAGTGAGTTCCAAAGACA ACTAAATGACTCAGTTTTATTGTTCGATGGTTCACTA ATCAGCACAGAATGGAACAATTGTTTTTATCTGCTTC GCTTGAGACC OCS Terminator GTCCTGCTTTAATGAGATATGCGAGAAGCCTATGAT (SEQ ID NO: 58) CGCATGATATTTGCTTTCAATTCTGTTGTGCACGTTG TAAAAAACCTGAGCATGTGTAGCTCAGATCCTTACC GCCGGTTTCGGTTCATTCTAATGAATATATCACCCGT TACTATCGTATTTTTATGAATAATATTCTCCGTTCAA TTTACTGATTGTACCCTACTACTTATATGTACAATAT TAAAATGAAAACAATATATTGTGCTGAATAGGTTTA TAGCGACATCTATGATAGAGCGCCACAATAACAAAC AATTGCGTTTTATTATTACAAATCCAATTTTAAAAAA AGCGGCAGAACCGGTCAAACCTAAAAGACTGATTAC ATAAATCTTATTCAAATTTCAAAAGTGCCCCAGGGG CTAGTATCTACGACACACCGAGCGGCGAACTAATAA CGCTCACTGAAGGGAACTCCGGTTCCCCGCCGGCGC GCATGGGTGAGATTCCTTGAAGTTGAGTATTGGCCG TCCGCTCTACCGAAAGTTACGGGCACCATTCAACCC GGTCCAGCACGGCGGCCGGGTAACCGACTTGCTGCCCCGAGAATTATGCAGCATTTTTTTGGTGTATGTGGGC CCCAAATGAAGTGCAGGTCAAACCTTGACAGTGACG ACAAATCGTTGGGCGGGTCCAGGGCGAATTTTGCGA CAACATGTCGAGGCTCAGCAGGACAtu g7 Terminator GATCCCCCGTCGACAGCTAGCTATATCATCAATTTAT (SEQ ID NO: 59) GTATTACACATAATATCGCACTCAGTCTTTCATCTAC GGCAATGTACCAGCTGATATAATCAGTTATTGAAAT ATTTCTGAATTTAAACTTGCATCAATAAATTTATGTT TTTGCTTGGACTATAATACCTGACTTGTTATTTTATC AATAAATATTTAAACTATATTTCTTTCAAGAT FAD2 Terminator GGATGATGGTGAAGAAATTGTCGACCTTTCTCTTGTC (SEQ ID NO: 60) TGTTTGTCTTTTGTTAAAGAAGCTATGCTTCGTTTTA ATAATCTTATTGTCCATTTTGTTGTGTTATGACATTTT GGCTGCTCATTATGTTATGTGGGAAGTTAGTGTTCAA ATGTTTTGTGTCGGTATTGTTCTTCTCATCGCTGTTTT GTTGGGATCGTAGAAATGTGACCTTCGGACAGTAAA ACTCTTGCGCTTGAGACCRbcS2b Terminator TCCCCTTTCTGGAATATTCAGCGTTGATTATTCTGGA (SEQ ID NO: 61) ACCCATTTCTATGTGGTCAATGCAAATTTAAGAAATT ATTTGCCGACTTAACAGTTGAGGAACTATTGTTTGA AAGTGAAAATGTTATTCCTATCAGTTTCTCTATAATT ATAGTTATCATTTCATTTCATTTTTGCCCTTAAATCTT TGAAATCTTATTTTTCGTTTAGCTCCGCTTGAGAC

[0054] In some embodiments, a method for AAV production is provided, comprising: i. preparing AAV plasmids comprising: a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3: and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; ii. introducing said plasmids into a vector capable of infecting a plant cell; iii. delivering said vector into a plant through a transient expression method; and iv. processing infiltrated leaves for AAVparticles. In some embodiments, the AAV produced is suitable for therapeutic use in a subject. In some embodiments, the subject is a human. In some embodiments, the vector is Agrobacterium tumefaciens. In some embodiments, the plant is Nicotiana benthamiana. In some embodiments, nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype. In some embodiments, nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype. In some embodiments, the VP1. VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3). In some embodiments, the method for AAV production further comprises a plasmid comprising a nucleic acid encoding a helper gene. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of Table 1. In some embodiments, the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of Table 1.

[0055] In some embodiments, a composition or system for AAV production is provided, comprising: a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; and wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; and c) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene. In some embodiments, nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype. In some embodiments, nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3). In some embodiments, the composition further comprises a plasmid comprising a nucleic acid encoding a helper gene. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of Table 1. In some embodiments, the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of Table 1. In some embodiments, the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins. In some embodiments, the transgene comprises TNFa, IL-2, or IL-4. In some embodiments, a method is provided for increasing genomic titer, capsid titer, and / or empty / full ratio of an AAV comprising a transgene, comprising introducing the composition or system of any of the AAV compositions described herein furthercomprising a transgene cassette encoding a transgene into a vector capable of infecting a plant cell, delivering said vector into a plant through a transient expression method, and processing infiltrated leaves for AAV particles. In some embodiments, a method is provided for reducing neutralizing antibody response in a subject to an AAV comprising a transgene, comprising introducing the composition or system of any one of the compositions described herein further comprising a transgene cassette encoding a transgene into a vector capable of infecting a plant cell, delivering said vector into a plant through a transient expression method, and processing infiltrated leaves for AAV particles, wherein the AAV particles produced are administered to a subject.

[0056] In some embodiments, a method is provided for AAV production, comprising: i. preparing AAV plasmids comprising: a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3: and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; c) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene; wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; and wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; ii. introducing said plasmids into a vector capable of infecting a plant cell; iii. delivering said vector into a plant through a transient expression method; and iv. processing infiltrated leaves for AAV particles. In some embodiments, the AAV produced is suitable for therapeutic use in a subject. In some embodiments, the subject is a human. In some embodiments, the vector is Agrobacterium tumefaciens. In some embodiments, the plant is Nicotiana benthamiana. In some embodiments, nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype. In some embodiments, nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3). In some embodiments, the method for AAV production further comprises a plasmid comprising a nucleic acid encoding a helper gene. In some embodiments, the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of Table 1. In some embodiments, the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of Table 1. In some embodiments, the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins. In some embodiments, the transgene comprises TNFa, IL-2, or IL-4.

[0057] In some embodiments, production of adeno-associated virus (AAV) vectors encoding toxic or highly bioactive transgenes such as cytokines, pro-apoptotic factors, or other immune-modulating proteins, is challenging in mammalian cell systems, as their expression leads to cellular stress, activation of inflammatory pathways, and induction of apoptosis in producer cells. In some embodiments, this results in reduced cell viability, impaired vector assembly, and ultimately substantially decreased AAV yields (>ell / L). In some embodiments, to mitigate, people have used weaker or inducible promoters, transcriptional repression elements, or microRNA-regulated constructs to suppress transgene expression during manufacturing.

[0058] In some embodiments, plants can potentially overcome the issues in mammalian cells. In some embodiments, plants have low to no expression of the AAV transgene in plants. In some embodiments, plant cells can compartmentalize and isolate toxic products in vacuoles or specific tissues. In some embodiments, plant cells have higher tolerance to toxic compounds.

[0059] In recent years, AAV has emerged as a preferred viral vector for gene therapy due to its ability to efficiently infect both non-dividing and dividing cells, maintain long-term transgene expression from episomal non-integrating AAV genomes in mammalian cells, and pose relatively low pathogenic risk to humans. In view of these advantages, recombinant adeno-associated virus (rAAV) presently is being used in gene therapy clinical trials for neurological disorders, ophthalmologic disorders, hearing disorders, hemophilia B, malignant melanoma, cystic fibrosis, and other diseases, and has recently passed FDA approval and BLA licensing for the treatment of the retinal degenerative disease Leber congenital amaurosis (LCA) and the motor neuron disease spino-muscular atrophy type 1 (SMA1).

[0060] AAV is able to infect a number of mammalian cells. Moreover, AAV transduction of human synovial fibroblasts is significantly more efficient than in similar murine cells, making AAV especially appealing for human gene therapy. Tropism of AAV differs significantly by serotype, underscoring the need to produce the AAV serotype most suitable for a particular target of gene therapy. rAAVs are currently produced in mammalian cells, including HEK 293T cells, COS cells, HeLa cells, KB cells, and other mammalian cell lines, and in insect cells, including Sf9, Sf21 , and other insect cells, using the baculovirus expression vector system (BEVS). See, e.g., U.S. Patents 6,156,303, 5,387.484, 5,741,683, 5.691,176, and 5,688.676; U.S. PGPub 2002 / 0081721, and International Patent Applications WO 2000 / 047757, WO2000 / 024916, WO 2003 / 042361, and WO 1996 / 017947, each of which is hereby expressly incorporated by reference in its entirety. The production of infectious AAV in non-mammalian, non-invertebrate plant cells and whole organisms was previously not known. The replication of parvoviral genomes, including, particularly, Dependovirus genomes, in non-mammalian, noninvertebrate plant cells and whole organisms, was similarly previously not known.

[0061] Current methods for producing large quantities of potent and high-purity clinical-grade AAV vectors rely on the use of mammalian cell culture or insect cell culture platforms. These platforms are expensive, non-standardized, and non-modular, and are difficult to scale from the process and development scale to production scales required to meet the global demand for AAV gene therapy products, representing a significant bottleneck. According to J. Fraser Wright, "cGMP lots in the range of 1016to 1018viral genomes will be required to meet the requirements of late-stage clinical development and product licensure for many recombinant AAV products, especially those aimed at the most commercially viable disease applications" (J. F. Wright. "Adeno-associated viral vector manufacturing: keeping pace with accelerating clinical development," Hum. Gene Ther., vol. 22, no. 8, pp. 913-914, Aug. 2011, hereby expressly incorporated by reference in its entirety). AAV production using transient gene expression in plants would address the most significant challenges currently found with conventional mammalian and insect cell-based production methods. Namely, dramatically reduced production costs and infrastructure costs, modular production, scalable production, and a standardized production method and process for all A AV-based viral vector products.

[0062] In the last 20 years, plants have become serious competitors to other production systems, such as bacteria, yeast, mammalian, or insect cells, for pharmaceuticals. Plants are robust, inexpensive to grow, and bring a low risk of contamination with endotoxins or mammalian pathogens, which can be an issue with mammalian and insect cell cultures. Unlike prokaryotic expression systems, plants are able to introduce post-translational modifications, such as glycosylation. In insect and yeast cells, glycosylation is limited to very simple and inconsistent high-mannose glycoforms. Any production system for pharmaceutical components, especially viral vectors, has to be quick in response to a sudden increase in demand. Transient expression in plants can be adjusted rapidly with very low manufacturing costs that are linearly scalable, with each individual plant representing a reproducible module of production, and is highly efficient in terms of biomass production and viral vector yield. The advantages of transient plant bio-factoriesare the ease of manipulation, speed, low cost, and high protein yield per weight of plant tissue, up to Ig / Kg of biomass (Gleba et al., 2007; Thuenemann et al., 2013).

[0063] The difficulties involved in scaling up rAAV production for clinical trials and commercialization using current mammalian and insect cell production systems can be significant, if not entirely prohibitive. For example, for certain clinical studies, more than 1015particles of rAAV per dose may be required, meaning up to IO20particles per manufactured batch for large patient cohorts for a licensed drug. An example would be SRP9001 for the treatment of Duchenne muscular dystrophy from Sarepta Therapeutics, with patient dosing of 2 x 1014vg / kg for children aged 3 months (average weight 6 kg) to 7 years (average weight 23 kg) old; and a global prevalence of -200,000 patients (Stark, A.E. Ann Trans! Med. 2015 Nov; 3(19): 287 and clinical trial NCT03375164). Analysis of AAV production costs across clinical (200L) or manufacturing (WOOL) scales calculated the inclusive cGMP production cost (Upstream, Downstream, QC, fill / finish) for 1 x 1014vg of AAV using either adherent cell culture, single-use bioreactors or fixed-bed bioreactors ranging from $8000-$25000 (Cameau. E. et al. Cell Gene Therapy Insights 2019; 5(11), 1663-1675). This would make production costs for large-scale cGMP global manufacturing for drug products such as SRP9001 prohibitively expensive using even optimized single-use stirred or fixed-bed mammalian cell bioreactors. Related difficulties associated with the production of AAV using known mammalian cell lines are recognized in the art. In addition, the insect cell BEVS system is subject to significant genome instability and genetic drift, preventing effective development of stable producer cell lines. There is also the possibility that a vector destined for clinical use produced in a mammalian and insect cell culture will be contaminated with undesirable, perhaps pathogenic, material present in a mammalian or insect cell. In view of these and other issues, there remains a need for alternative and improved methods of efficiently, safely, and economically producing a large amount of infectious rAAV particles.

[0064] In contrast to cell culture-based production systems, plant biomass generation does not require the construction of expensive fermentation facilities, and correspondingly, scale-up production can be achieved without the need to construct duplicate facilities. As a result, plant biomass generation and upstream processing capacity can be operated and scaled in a capitalefficient manner with established agriculture practices. One 4-6 week old plantlet, following infiltration / production and purification, is estimated to be equivalent to one liter of suspension-adapted mammalian cells based on experimentally determined yields of up to Ig / kg of plantbiomass for optimized recombinant protein production in N. benthamiana. By comparison, plant-made biologies cost significantly less than current cell culture-based systems because mammalian cell cultures require considerable startup investment and expensive growth media (Lai H, Chen Q Plant Cell Rep. 2012 Mar; 31(3):573-84). Plants also outpace the scalability of other expression systems, as recombinant protein-expressing biomass can be produced on an agricultural scale without the need to build duplicated bioreactors and associated facilities (Chen Q. Biological Engineering Transactions. 2008;1:291-321). In contrast to bacterial cells, plants can produce large functional pharmaceutical proteins that require the proper post-translational modification of proteins, including glycosylation and the assembly of multiple hetero-subunits, similar to mammalian or insect cells (Lai H, et al., Proc Natl Acad Sci U S A. 2010 Feb 9; 107(6):2419-24.)

[0065] Described herein are rapid, scalable, and cost-effective methods for producing clinical-grade recombinant replication-defective adeno-associated viral vectors in plants.

[0066] AAV is a non-enveloped, replication-defective virus around 20 nm in diameter with a single- stranded DNA genome approximately 4.8 kilobases long. Over 100 serotypes of AAV have been identified, with at least 12 serotypes being characterized to some degree. These AAV serotypes exhibit remarkable divergence, such as the specific host cell receptor or primary receptor used for entry, and preference for certain host cell types (e.g., muscle cells, neurons, astrocytes, hepatocytes). For example, AAV1, 4, 5, and 6 bind to N- or O-linked sialylated proteoglycans, AAV9 binds to galactose, and AAV2 and 3 bind to heparin sulfate proteoglycans. AAV2 has historically been the best studied and utilized, but usage of different serotypes depending on their unique properties is possible. The AAV genome comprises three genes: REP, CAP, and AAP, but internal open reading frames and promoters in these genes result in multiple different proteins or protein fragments. REP encodes for REP78, REP68, REP52, and REP40, which are all involved in genome replication and packaging of viral particles. CAP encodes for VP1, VP2, and VP3. which form the icosahedral viral capsid. AAP, which is found within the CAP sequence in a different reading frame, encodes for the assembly-activating protein (AAP), which is needed for proper capsid formation at least in AAV2, but dispensable in other AAV serotypes. The nucleic acid material or genome that gets packaged into the AAV particles corresponds to the sequence found flanked by inverted terminal repeats (ITR). In wild-type viruses, the ITR flank the REP, CAP, and AAP gene sequences. For recombinant AAV, different transgenes, including but not limited to genes encoding an enzymatic marker (e.g., LacZ), genes encoding fluorescentproteins (e.g., GFP, EGFP), genes encoding optogenetic proteins (e.g., Chr2, ArctT, Cl VI), genes encoding genetic sensors of cell metabolism, calcium, and electrical activity (e.g., GCaMPs, rCaMPs, genetically encoded voltage sensors), genes encoding drag selection markers, genes encoding gene and RNA editing proteins (e.g., zinc finger nucleases, TALENs, CRISPR-Cas proteins, Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9. Neisseria meningitidis Cas9. Francisella novicidia Cas 12a or Casl2b, Prevotella sp. p5-125 Casl3a, Casl3b, Casl3c, or Casl3d, Porphyromonas gulae Casl3a, Casl3b, Casl3c, or Casl3d, Riemerella anatipestifer Casl3a, Casl3b, Casl3c, or Casl3d), genes to regulate or induce transgene expression (e.g., Dox inducible gene switches, Cumate inducible gene switches, PhyB-light regulated gene switches) or genes to treat a disease (e.g., CFTR for cystic fibrosis, Factor IX for hemophilia B, RPE65 for Leber congenital amaurosis, neurotrophins for neurodegenerative diseases). By excluding the REP proteins from the ITR-flanked region, the transgenes exist as episomes and can be expressed transiently by the host instead of integrating into the host genome. Hybrid AAV particles combining two or more serotypes can also be done to alter transducing efficiencies, cell type tropism, or affinity to host cell receptors.

[0067] As a replication-defective virus, AAV requires a helper virus to replicate efficiently. Co-infection with an adenovirus accomplishes this but leads to adenoviral contamination during purification. To avoid this, expression (either from the nucleic acid vector containing the AAV genes, or previously engineering the host cell) of the El, E2A, E4, and VA regions of the adenovirus genome provides an additional set of components needed for efficient AAV production. In some embodiments, the El, E2A, and VA regions are only needed for efficient AAV production when using an endogenous AAV promoter. In some embodiments, the AAV genes can be driven with other promoters, such as constitutive promoters, inducible promoters, other viral promoters, mammalian promoters, bacterial promoters, fungal promoters, or plant promoters. In some embodiments, only the E4 region is needed for AAV replication. In some embodiments, the adenovirus type 5 E4orf6 gene (Ad5 E4orf6) is provided with the AAV expression vectors during transformation of the plant to increase AAV yield.

[0068] In some embodiments, AAV particles are produced under sterile conditions and under regulated or controlled procedures. Methods for maintaining and ensuring sterility may adhere to good manufacturing practice (GMP), good tissue practice (GTP), good laboratory practice (GLP), and good distribution practice (GDP) standards. Methods for maintaining andensuring sterility include but are not limited to high-efficiency particulate air (HEPA) filtration, wet or dry heat, radiation, e.g., X-rays, gamma rays, or UV light, sterilizing agents or fumigants, such as ethylene oxide, nitrogen dioxide, ozone, glutaraldehyde, formaldehyde, peracetic acid, chlorine dioxide, or hydrogen peroxide, aseptic filling of sterile containers, packaging in plastic film or wrap, or vacuum sealing.

[0069] AAV are purified with methods to provide optimal yield of functional viral particles while excluding potential contaminants that may harm individuals and avoiding purification of non-functional empty capsids. Toward this goal, AAV can be purified using techniques known in the art, including but not limited to extraction, freeze-thawing, homogenization, permeabilization, centrifugation, density gradient centrifugation, CsCl gradient centrifugation, iodixanol gradient centrifugation, ultracentrifugation, fractionation, precipitation, SDS-PAGE, native PAGE, size exclusion chromatography, liquid chromatography, gas chromatography, hydrophobic interaction chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, affinity chromatography, heparin sulfate affinity chromatography, sialic acid affinity chromatography, immunoaffinity chromatography, metal binding chromatography, nickel column chromatography, epitope tag purification, or lyophilization, or any combination thereof.

[0070] As with any other group of organisms, certain plants have found favor for use in research or production due to properties such as size, growth rate, ease of culture, available pathogens or vectors, disease resistance, adaptability to external conditions, light requirements, ease of genetic manipulation, types of phytochemicals produced, or availability of a genomic sequence. Plants that are useful for these properties or any other desirable property include but are not limited to Nicotiana, Nicotiana benthamiana, Nicotiana tabacum, Arabidopsis, Arabidopsis thaliana, Solarium, Solarium tuberosum, Solatium lycopersicum, Solarium lycopersicoides, Cannabis, Cannabis sativa, Fagopyrum, Fagopyrum esculentum, Oryza, Oryza sativa, Zea, Zea mays, Hordeum, Hordeum vulgare, Selaginellai, Selaginella moellendorffii, Brachypodium, Brachypodium distachyon, Lotus, Lotus japonicus, Lemna, Lemna gibba, Medicago, Medicago truncatula, Mimulus, Mimulus guttatus, Physcomitrella, Physcomitrella patens, Populus, Populus trichocarpa, Lactuca, Lactuca sativa, or any plant species able to be transformed by Agrobacterium tumefaciens. In some embodiments, the plant belongs to Nicotiana. In some preferred embodiments, the plant is Nicotiana benthamiana.

[0071] Agrobacterium tumefaciens is a bacterium pathogenic to plants, causing galls, crown galls, or tumors in the plant. A. tumefaciens accomplishes this through the tumor-inducing plasmid (Ti plasmid), which comprises a T-DNA region which gets transferred to the host plant and a pathogenicity island or virulence region of genes encoding a type IV secretion mechanism used to perform said transfer. The T-DNA region comprises genes encoding proteins that synthesize plant hormones such as auxin and cytokinin, which cause growth of the galls or tumors. By removing these genes (to abolish formation of the disease) and inserting desirable genes for expression, A. tumefaciens is a potent tool for genetically engineering plants. Successful transformation of A. tumefaciens or plants may be selected by, for example, resistance to neomycin, kanamycin, or G418 (geniticin) through expression of neomycin phosphotransferase. More information about transformation of plants using A. tumefaciens can be found in U.S. Patent 5,792,935, hereby expressly incorporated by reference in its entirety.

[0072] As used herein, “plant promoter” refers to the untranslated nucleic acid sequence upstream of a coding sequence that initiate transcription. Plants can have promoters responsive to certain environmental conditions, including but not limited to light-responsive promoters, stress-responsive promoters, plant hormone-responsive promoters, sucrose-responsive promoters, low-oxygen responsive promoters, or the nopaline synthase promoter. For the production and subsequent purification of AAV and other viruses or proteins in plants, strong constitutive promoters are typically desired. In some embodiments, some strong constitutive promoters used include but are not limited to Cauliflower Mosaic Virus 35S promoter, Cowpea Mosaic Virus promoter, opine promoters, ubiquitin promoters, rice actin 1 promoter, or maize alcohol dehydrogenase 1 promoter. In some embodiments, a pEAQ-HT vector is used to transform plants either transiently or stably using A. tumefaciens (agroinfiltration). This pEAQ vector uses the Cowpea Mosaic Virus promoter sequence (with a U162C mutation to enhance activity) within the T-DNA to obtain high rates of protein expression without extraneous virus production in plants. However, in other embodiments, different plant expression vectors such as pBINPLUS, pPZP3425, pPZP5025, pPZPTRBO, pJLTRBO, or pBY030-2R can be used. More information about the pEAQ vectors is provided in U.S. Patent 8,674,084, hereby expressly incorporated by reference in its entirety.

[0073] As used herein, the term “plantlet” refers to young plants. Relative to fully grown plants, plantlets are smaller, therefore easier to handle, and experience rapid growth andcellular activity. Tn some embodiments, small-scale purification of AAV involves the use of at least 1, 2, 3, 4, 5, 6, 7. 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 plantlets. In other embodiments, larger-scale purification of AAV can be scaled up to use at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, 10000, 20000, 30000, 40000, or 50000 plants.

[0074] The term “purity” of any given substance, compound, or material as used herein refers to the actual abundance of the substance, compound, or material relative to the expected abundance. For example, the substance, compound, or material may be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure, including all decimals in between. Purity may be affected by unwanted impurities, including but not limited to nucleic acids, DNA, RNA, nucleotides, proteins, polypeptides, peptides, amino acids, lipids, cell membrane, cell debris, small molecules, degradation products, solvent, carrier, vehicle, or contaminants, or any combination thereof. In some embodiments, the AAV product is substantially free of host cell proteins, host cell nucleic acids, plasmid DNA, empty viral vectors, AAV particles with incomplete protein composition and oligomerized structures, or contaminating viruses, e.g., non-AAV, lipid-enveloped viruses, Heat shock protein 70 (HSP70), Lactate dehydrogenase (LDH), proteasomes, contaminant non-AAV viruses, host cell culture components, process -related components, mycoplasma, pyrogens, bacterial endotoxins, and adventitious agents. Purity can be measured using technologies including but not limited to electrophoresis, SDS-PAGE, capillary electrophoresis, PCR, rtPCR, qPCR, chromatography, liquid chromatography, gas chromatography, thin-layer chromatography, enzyme-linked immunosorbent assay (ELISA), spectroscopy, UV-visible spectrometry, infrared spectrometry, mass spectrometry, nuclear magnetic resonance, gravimetry, or titration, or any combination thereof.

[0075] Producing AAV particles in plant or plant material using techniques such as agroinfiltration results in greater purity of AAV compared to techniques known in the art, such as production in mammalian or insect cells. In some embodiments, plant-derived AAV particles are free of animal or mammalian cellular components, animal or mammalian-specific pathogens, including viruses, bacteria, protozoans, and fungi, serum, bovine serum, antibiotics, or hormones, or any combination thereof.

[0076] The term “yield” of any given substance, compound, or material as used herein refers to the actual overall amount of the substance, compound, or material relative to the expected overall amount. For example, the yield of the substance, compound, or material may be at least 80,85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% of the expected overall amount, including all decimals in between. Yield may be affected by the efficiency of a reaction or process, unwanted side reactions, degradation, quality of the input substances, compounds, or materials, or loss of the desired substance, compound, or material during any step of the production.

[0077] Producing AAV particles in plant or plant material using techniques such as agroinfiltration results in greater yield of AAV compared to techniques known in the art. such as production in mammalian or insect cells. In some embodiments, one 4-6 week old plantlet yields at least 107, 108, 109. 1010. 1011, 1012. 1013, or 1014AAV particles.

[0078] The invention is generally disclosed herein using affirmative language to describe the numerous embodiments. The invention also includes embodiments in which subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, or procedures.

[0079] Also disclosed herein, in some embodiments, are recombinant nucleic acid vectors comprising any one or more of the nucleic acid molecules disclosed herein. Also disclosed herein, in some embodiments, are proteins encoded by any one of the nucleic acid molecules or nucleic acid vectors disclosed herein. Also disclosed herein, in some embodiments, are AAV particles comprising any one or more of the nucleic acid molecules, nucleic acid vectors, or proteins disclosed herein.

[0080] Also disclosed herein, in some embodiments, are plant cells comprising any one or more of the nucleic acid molecules, nucleic acid vectors, proteins, or AAV particles disclosed herein. Also disclosed herein, in some embodiments, are plants comprising any one of the plant cells disclosed herein. In some embodiments, the plant cell or plant belong to the genera Nicotiana, Arabidopsis, Solanum, Cannabis, Fagopyrum, Oryza, or Zea. In some embodiments, the plant is a Nicotiana species. In some embodiments, the plant is Nicotiana benthamiana or Nicotiana tabacum.

[0081] Also disclosed herein, in some embodiments, are leaves, stems, flowers, or roots from any one of the plant cells or plants disclosed herein.Methods of making and use

[0082] Also disclosed herein are methods of producing functional AAV particles in a plant. In some embodiments, the methods comprise transforming the plant with at least one recombinant nucleic acid vector comprising nucleic acid sequences that encode for components of-SO-the AAV particles or components that are involved in the assembly of the AAV particles, growing the plant under conditions where the AAV particles are expressed and assembled in the plant, and isolating the AAV particles from the plant. In some embodiments, the step of transforming the plant is done by agroinfiltration. In some embodiments, the nucleic acid sequence that encodes for components of the AAV particles is codon-optimized for the plant. In some embodiments, the plant belongs to the genera Nicotiana. Arabidopsis, Solanum, Cannabis, Fagopyrum, Oryza, Lactuca, or Zea. In some embodiments, the plant is a Nicotiana, Lactuca, or Cannabis species. In some embodiments, the plant is Nicotiana benthamiana, Nicotiana tabacum, Lactuca sativa, or Cannabis sativa. In some embodiments, the components of the AAV particles or components that are involved in the assembly of the AAV particles comprise a REP protein, a CAP protein, an AAP protein, or an Ad5 E4orf6 protein, or any combination thereof.

[0083] In any of the methods disclosed herein, isolating the AAV particles comprises centrifugation, filtration, and / or chromatography. In some embodiments, the chromatography is affinity, ion exchange, anion exchange, size exclusion, or hydrophobic interaction chromatography. In some embodiments, at least 104, 105, 106, 107, 108, 109, IO10, 1011, 1012, 1013, or 1014AAV particles are isolated from the plant. In some embodiments, at least 1012, 1013, or 1014AAV particles are isolated from the plant. In some embodiments, the AAV particles are capable of infecting a mammalian cell, optionally a human cell, optionally HEK293T.

[0084] In any of the methods disclosed herein, the methods further comprise administering the AAV particles to a mammal. In some embodiments, the mammal is a human.

[0085] Also disclosed herein are methods of gene therapy. In some embodiments, the methods comprise administering an AAV particle produced and isolated by any one of the methods disclosed herein to a cell of a subject in need thereof.

[0086] Also disclosed herein are the recombinant nucleic acid vectors or AAV particles disclosed herein for use as a medicament.

[0087] Also disclosed herein are the recombinant nucleic acid vectors or AAV particles disclosed herein for use in treating, inhibiting, or ameliorating a disease such as, an inborn error in metabolism, enzyme deficiencies, Pompe disease, Danon disease, neurodegenerative disorders, Parkinson’s disease, Alzheimer’s disease, motor neuron disease, muscular dystrophies, Duchenne muscular dystrophy, retinal degenerative disease, retinitis pigmentosa, Usher syndrome, Stargardt disease, or genetic causes of deafness.

[0088] Also disclosed herein are the AAV particles produced by any of the methods disclosed herein for use in the treatment of a disease.

[0089] Also disclosed herein are the AAV particles produced by any of the methods disclosed herein for use in the manufacture of a medicament.

[0090] In some embodiments, the helper gene comprises the nucleic acid sequence of any one of SEQ ID NOs: 13-27, or a sequence disclosed in Table 1.

[0091] In some embodiments, optimization of the stoichiometry of VP1, VP2, VP3, Rep 78, and Rep52 in AAV particles generated in plants can be achieved by the use of preferred regulatory elements that drive expression of the genes in a preferred manner. In some embodiments, the preferred manner comprises a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3). In some embodiments, the preferred regulatory elements can comprise specific promoters, UTRs, and / or terminators.

[0092] In some embodiments, the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a promoter comprising the nucleic acid sequence of any one of SEQ ID NOs: 28-45, or a sequence disclosed in Table 1.

[0093] In some embodiments, the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a UTR comprising the nucleic acid sequence of any one of SEQ ID NOs: 46-52, or a sequence disclosed in Table 1.

[0094] In some embodiments, the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a terminator comprising the nucleic acid sequence of any one of SEQ ID NOs: 53-61, or a sequence disclosed in Table 1.EXAMPLES

[0095] Some aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the present disclosure. Those in the art will appreciate that many other embodiments also fall within the scope of the invention, as it is described herein above and in the claims.Example 1: Addressing the Manufacturing Bottleneck in Gene Therapies Through AAV Production in Whole Nicotiana benthamiana Plants

[0096] The demand for adeno-associated virus (AAV) vectors is increasing due to their role in gene therapies for various genetic disorders (FIG. 1A). However, current production methods using mammalian and insect cell systems are costly, slow, and hard to scale, limiting accessibility (FIG. IB). High production costs result in multi-million-dollar price tags for approved gene therapies, which are often unaffordable for patients, especially in low- and middle-income countries. With thousands of gene therapies in development, traditional cell culture-based production straggles to meet the growing demand, as it requires specialized facilities and lengthy scale-up times. Moreover, inconsistent vector yields and quality impact clinical reliability, especially for progressive genetic disorders where timely treatment is critical. To address these challenges, an innovative, plant-based AAV production system was developed that is cost-effective, scalable, reliable, and faster, ensuring wider accessibility to life-saving treatments (FIG.1C). A split-Rep and split-Cap system was utilized, where the VP1, VP2, and VP3 capsid proteins, along with the Rep78 and Rep52 proteins, are split across separate plasmids (FIG. 2A-2B). This approach enhances AAV production efficiency, genetic stability, and scalability while minimizing the toxic effects of high Rep expression levels.

[0097] Significant variability in AAV yields was observed using the traditional three-vector (Rep, Cap, Helper) system (FIG. 2A, left panel). It was hypothesized that by separating VP1, VP2, and VP3 and Rep 52 and 78 onto different plasmids, their expression levels can be independently controlled, ensuring consistency in capsid assembly and genome loading (FIG. 2A right panel). Plasmids for AAV9-CMV-GFP production were generated by splitting Cap and Rep proteins across separate plasmids. These plasmids were introduced into Agrobacterium tumefaciens, which was used to deliver the vectors into Nicotiana benthamiana plants through a transient expression method. The infiltrated leaves were harvested five days later and homogenized. The expression levels of VP1, VP2, VP3, Rep78, and Rep52 were analyzed using western blot and Jess for stoichiometry and relative expression (FIG. 2B). Different combinations of VP1, VP2, and VP3 split, as well as for Rep 78 and Rep 52, were tested, as shown in FIG. 2B. The western blot data looking at the protein level expression of individual Capsid and Rep proteins suggest that merely splitting the VP 1 / 2 / 3 does not ensure correct stoichiometry. Manipulating the start sites for each Capsid protein isoform helps in regulation of Cap VP expression. Weak startsites for VP2 in FL VP1 / 2 / 3 were tested; strong start sites for VP 2 and 3 for VP2 / 3 were tested; and a strong start site for VP3 for the VP3 isoform was tested. A weaker start site for VP2 isoform in VP1 and VP2 plasmid provided the ideal stoichiometry using a plant-optimized Rep coding sequence. Consolidation of the split system to produce AAV in plants using a 3-plasmid system helped in achieving high titers (FIG. 3A) and high batch-to-batch consistency in the capsid titer (FIG. 3B).

[0098] The performance of the plant-based system was compared to the traditional HEK-293 cell-based method, whereby Rep and Cap were expressed from a single plasmid. Capsid titer was measured using ELISA, and combined UV / Visible light absorbance, Dynamic Light Scattering (DLS), and static light scattering (SLS) was performed on the purified material using Stunner (FIG. 3C). As shown in FIG. 3D, when dosed in Non-human Primates (NHP), Plant AAV9-CMVGFP mRNA expression have similar or higher levels of GFP mRNA expression compared to the HEK AAV9- CMV-GFP expression. FIG. 3E summarizes findings from the preceding figures: Plant-based AAV production using a split-Cap and split-Rep plasmid system significantly enhances yield and reproducibility; The natural stoichiometry of AAV vectors prevents toxicity from overexpression, and reduces recombination issues, resulting in more consistent vector production; The split-Cap system potentially allows for the creation of hybrid AAV vectors by mixing and matching VP1, VP2, and VP3 proteins from various serotypes, which could improve tropism and immune evasion in future applications.

[0099] The natural stoichiometry of AAV capsid proteins is 1:1:10 (VP1:VP2:VP3), but achieving this ratio from a single plasmid is challenging due to competing transcription and translation. By separating VP1, VP2, and VP3 onto different plasmids, their expression levels were independently controlled, ensuring proper capsid assembly. It was observed that modifying the expression of VP1, VP2, VP3, Rep78, and Rep52 from separate plasmids optimized capsid formation, generated higher AAV vector production efficiency. More than lel5 AAV capsid particles were produced from just 1kg of plant biomass (approximately 2 liters of plant homogenate for downstream processing) (FIG. 3B).

[0100] Herein, it is demonstrated for the first time that plant-based AAV production using a split-Cap and split-Rep plasmid system significantly enhances AAV yield and scalability. This method preserves the natural stoichiometry of AAV vectors, prevents toxicity from overexpression, and reduces recombination issues, resulting in more consistent vector production.Moreover, the split-Cap system potentially allows for the creation of hybrid AAV vectors by mixing and matching VP1, VP2, and VP3 proteins from various serotypes, which could improve tropism and immune evasion in future applications.Example 2: Characterization of Plant-made AAVs and a Side-by-side Comparison with HEK-derived AAV

[0101] AAV2 and AAV9-CMV-GFP were produced in Nicotiana benthamiana by infiltrating leaves with Agrobacterium carrying the necessary plasmids. After five days, leaves were harvested, homogenized, and purified using tangential flow filtration, affinity capture, and iodixanol gradient purification mirroring HEK293-based methods. Both plant- and HEK-derived AAVs were characterized via qPCR, ELISA, TEM, SDS-PAGE, sterility, endotoxin, and mycoplasma testing (FIG. 4A). Infectivity was assessed in vitro, ex vivo, and in vivo, and post-translational modifications were analyzed via mass spectrometry.

[0102] Agrobacterium carrying recombinant plasmids successfully infiltrated N. benthamiana leaf cells, enabling AAV vector assembly in plants yielding more than lel4 viral genomes per kilogram of biomass (FIG. 4A). Using standard AAV purification methods, comparable recovery rates to mammalian cell-derived AAVs were obtained. Quality assessments confirmed -90% full particles, endotoxin levels well below FDA guidelines, and absence of bacterial, fungal, or mycoplasma contamination similar to HEK293T-derived AAVs (FIG. 4A). Both plant- and HEK-derived AAVs exhibited proper VP1, VP2, and VP3 ratios on SDS-PAGE, with -90% full capsids confirmed by TEM and ELISA (FIG. 4B). Better transgene expression and reduced neutralizing antibody profile from plant- produced AAV in Non-human Primates was observed compared to HEK-derived AAVs, despite identical transduction rates (FIGs. 4D-4F). Finally, a thorough post-translational modification analysis showed a very similar profile, besides slight differences in phosphorylation (FIG. 4C).

[0103] As summarized in FIG. 4G, transient AAV production in plants is demonstrated herein, reducing costs by over tenfold and significantly shortening scale-up time. Since each plant serves as an independent, reproducible production unit, scalability is highly reliable. Additionally, the plant-based platform integrates with existing purification workflows used in AAV production, making it easily adaptable. A head-to-head comparison of the plant-produced AAVs with thosefrom the HEK origin showed a similar analytical profile, and better activity in the Non-Human Primates.Example 3: Screening of Helper Genes

[0104] Nine different helper genes were screened in 14 different combinations, to identify the combinations that increase AAV yield. A table of helper genes that were tested and their function is provided in FIG. 5. A table listing the 14 different helpers tested is provided in FIGs. 6A-6B. The addition of helper proteins assists in obtaining higher AAV yield, while keeping the VP123 stoichiometry unaffected, as shown in FIG. 7 and FIGs. 8A-8B.Example 4: Production of Bioactive Transgenes

[0105] Production of adeno-associated virus (AAV) vectors encoding toxic or highly bioactive transgenes, such as cytokines, pro-apoptotic factors, or other immune-modulating proteins, is challenging in mammalian cell systems, as their expression leads to: cellular stress, activation of inflammatory pathways, and induction of apoptosis in producer cells. This results in reduced cell viability, impaired vector assembly, and ultimately substantially decreased AAV yields (>ell / L). To mitigate, people have used: weaker or inducible promoters, transcriptional repression elements, or microRNA-regulated constructs to suppress transgene expression during manufacturing (FIG. 9A-9B).

[0106] Plants can potentially overcome the issues in mammalian cells: low to no expression of the AAV transgene in plants; plant cells can compartmentalize and isolate toxic products in vacuoles or specific tissues; and higher tolerance to toxic compounds. Production of inflammatory cytokines TNFa, IL2, and IL4 in plants was tested (FIG. 10). The experiment consisted of: 1) Construct design and synthesis; 2) Cloning and transformation; 3) Syringe infiltration; and 4) Harvest 5 days post-infiltration.Example 5: Production of AAV9 vectors expressing cytotoxic cytokines using transient gene transfer of split packaging constructs to N. benthamiana plants by agroinfiltration

[0107] N. benthamiana plants were transiently infiltrated with separate agrobacterial strains transformed with binary T-DNA plasmids encoding AAV9 VP1, VP2, and VP3, AAV2 Rep 78 and REP52, AAV9 AAP, and adenoviral or HSV helper genes and rAAV genomicconstructs with transgene cassettes encoding the following cytokines: TNFa, TL-2, IL-2, and a positive control EGFP cassette. rAAV vectors constitutively expressing cytotoxic cytokines such as TNF1, IL-2, and IL-4 do not produce well in HEK293 suspension cell culture. FIG. 11A-11C show data from 4 production batches of AAV9 vectors constitutively expressing either TNFa, IL-2, or IL-2 under the control of the CMV promoter, with an AAV9-EGFP vector as a positive control. Genomic titers (FIG. 11A), capsid titers (FIG. 11B), and empty / full ratios (FIG. 11C) for each AAV9 vector (measured from the crude plant lysate) expressing the cytotoxic cytokines are comparable or higher than the control AAV9-GFP vector, unlike rAAV vectors expressing cytotoxic payloads when packaged in HEK293 suspension cells, where genomic titers and capsid titers are typically >10X lower than for rAAV vectors packaging non-cytotoxic transgene cassettes.Example 6: Using purified AAV particles for gene therapy

[0108] The recombinant AAV viral particles produced in the preceding examples are intact and infective. These particles can be used for gene therapy purposes or other therapeutic purposes. Particles can be used for ex vivo and in vivo treatments or applications. Particles can be administered enterally, parenterally, orally, sublingually, buccally, intranasally, intraocularly, intraaurally, epidurally, epicutaneously, intra-arterially, intravenously, intraportally, intraarticularly, intramuscularly, intradermally, peritoneally, subcutaneously, or directly to an organ, tissue, cancer, or tumor. Particles can also be administered to isolated cells from a patient or individual, such as T cells, Natural Killer cells, B cells, macrophages, lymphocytes, stem cells, bone marrow cells, or hematopoietic stem cells. Particles purified from plants offer improved safety profiles, yield, and efficacy over viral particles purified by other methods, such as from mammalian cell culture or insect cell culture.

[0109] In at least some of the previously described embodiments, one or more elements used in an embodiment can interchangeably be used in another embodiment unless such a replacement is not technically feasible. It will be appreciated by those skilled in the art that various other omissions, additions, and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims.

[0110] With respect to the use of substantially any plural and / or singular terms herein, those having skill in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for the sake of clarity.

[0111] It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation, no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and / or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general, such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general, such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A,B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”

[0112] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0113] As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third, and upper third, etc. As will also be understood by one skilled in the art, all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

[0114] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

[0115] All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.

Claims

WHAT IS CLAIMED IS:

1. A system for AAV production comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; and wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids.

2. The system of claim 1, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.

3. The system of any of the preceding claims, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from the same AAV serotype.

4. The system of any of the preceding claims, wherein the VP1, VP2, and / or VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).

5. The system of any of the preceding claims, further comprising a plasmid comprising a nucleic acid encoding a helper gene.

6. The system of any of the preceding claims, wherein the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11 , or 12 or a sequence disclosed in Table 1.

7. The system of any of the preceding claims, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.

8. A method for AAV production comprising:i. preparing AAV plasmids comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; andb) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; ii. introducing said plasmids into a vector capable of infecting a plant cell;iii. delivering said vector into a plant, preferably through a transient expression method; and iv. processing infiltrated leaves for AAV particles.

9. The method of claim 8, wherein the AAV produced is suitable for therapeutic use in a subject.

10. The method of claim 9, wherein the subject is a human.

11. The method of any of the preceding method claims, wherein the vector is Agrobacterium tumefaciens.

12. The method of any of the preceding method claims, wherein the plant is Nicotiana benthamiana.

13. The method of any of the preceding method claims, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.

14. The method of any of the preceding method claims, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.

15. The method of any of the preceding method claims, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).

16. The method of any of the preceding method claims, further comprising a plasmid comprising a nucleic acid encoding a helper gene.

17. The method of any of the preceding method claims, wherein the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.

18. The method of any of the preceding method claims, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.

19. A system for AAV production comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3; and b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; and c) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene.

20. The system of claim 19, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.

21. The system of any of claims 19 or 20, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.

22. The system of any of claims 19-21, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).

23. The system of any of claims 19-22, further comprising a plasmid comprising a nucleic acid encoding a helper gene.

24. The system of any of claims 19-23, wherein the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.

25. The system of any of claims 19-24, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.

26. The system of any of claims 19-25. wherein the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins.

27. The system of claim 26, wherein the transgene comprises TNFa, IL-2, or IL-4.

28. A method for increasing genomic titer, capsid titer, and / or empty / full ratio of an AAV comprising a transgene, comprising introducing the composition of any one of claims 19-27 into a vector capable of infecting a plant cell, delivering said vector into a plant through a transient expression method, and processing infiltrated leaves for AAV particles.

29. A method for reducing a neutralizing antibody response in a subject to an AAV comprising a transgene, comprising introducing the system of any one of claims 19-27 into a vector capable of infecting a plant cell, delivering said vector into a plant through a transient expression method, and processing infiltrated leaves for AAV particles, wherein the AAV particles produced are administered to a subject.

30. A method for AAV production comprising:i. preparing AAV plasmids comprising:a) nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3;b) nucleic acid sequences encoding AAV Rep78 and Rep52 proteins; andc) one or more recombinant adeno-associated virus genomic constructs comprising a transgene cassette encoding a transgene;wherein the VP1, VP2, and VP3 nucleic acid sequences are each present on separate plasmids; wherein the Rep78 and Rep52 nucleic acid sequences are each present on separate plasmids; ii. introducing said plasmids into a vector capable of infecting a plant cell;iii. delivering said vector into a plant through a transient expression method; andiv. processing infiltrated leaves for AAV particles.

31. The method of claim 30. wherein the AAV produced is suitable for therapeutic use in a subject.

32. The method of claim 31, wherein the subject is a human.

33. The method of any one of claims 30-32, wherein the vector is Agrobacterium tumefaciens.

34. The method of any one of claims 30-33, wherein the plant is Nicotiana benthamiana.

35. The method of any one of claims 30-34, wherein nucleic acids encoding the VP1, VP2, and / or VP3 proteins are from more than one AAV serotype.

36. The method of any one of claims 30-35, wherein nucleic acids encoding the VP1, VP2, and VP3 proteins are from the same AAV serotype.

37. The method of any one of claims 30-36, wherein the VP1, VP2, and VP3 nucleic acid sequences are configured to assemble into a protein capsid with a 1:1:10 ratio (VP1:VP2:VP3).

38. The method of any one of claims 30-37, further comprising a plasmid comprising a nucleic acid encoding a helper gene.

39. The method of any one of claims 30-38, wherein the VP1, VP2, and VP3 nucleic acid sequences are any of the VP1, VP2, and VP3 nucleic acid sequences of any one or more of SEQ ID Nos: 3, 7, 8, 9, 10, 11, or 12 or a sequence disclosed in Table 1.

40. The method of any one of claims 30-39, wherein the Rep78 and Rep52 nucleic acid sequences are any of the Rep78 and Rep52 nucleic acid sequences of any one or more of SEQ ID Nos: 4, 5, 6, or 10 or a sequence disclosed in Table 1.

41. The method of any of claims 30-40, wherein the transgene comprises a cytokine, pro-apoptotic factor, or other immune-modulating proteins.

42. The method of claim 41, wherein the transgene comprises TNFa, IL-2, or IL-4.

43. The system or method of any one of claims, 5, 16, 23, or 38, wherein the helper gene comprises the nucleic acid sequence of any one of SEQ ID NOs: 13-27 or a sequence disclosed in Table 1.

44. The system or method of any one of the preceding claims, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a promoter comprising the nucleic acid sequence of any one of SEQ ID NOs: 28-45 or a sequence disclosed in Table 1.

45. The system or method of any one of the preceding claims, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a UTR comprising the nucleic acid sequence of any one of SEQ ID NOs: 46-52 or a sequence disclosed in Table 1.

46. The system or method of any one of the preceding claims, wherein the nucleic acid sequences encoding AAV capsid proteins VP1, VP2, and VP3 and / or nucleic acid sequences encoding AAV Rep78 and Rep52 proteins further comprise a terminator comprising the nucleic acid sequence of any one of SEQ ID NOs: 53-61 or a sequence disclosed in Table 1.